id	sid	tid	token	lemma	pos
cord-348535-tvs1snq8	1	1	key	key	JJ
cord-348535-tvs1snq8	1	2	:	:	:
cord-348535-tvs1snq8	1	3	cord-348535-tvs1snq8	cord-348535-tvs1snq8	NNS
cord-348535-tvs1snq8	1	4	authors	author	NNS
cord-348535-tvs1snq8	1	5	:	:	:
cord-348535-tvs1snq8	1	6	Ottaviani	Ottaviani	NNP
cord-348535-tvs1snq8	1	7	,	,	,
cord-348535-tvs1snq8	1	8	Silvia	Silvia	NNP
cord-348535-tvs1snq8	1	9	;	;	:
cord-348535-tvs1snq8	1	10	Stebbing	Stebbing	NNP
cord-348535-tvs1snq8	1	11	,	,	,
cord-348535-tvs1snq8	2	1	Justin	Justin	NNP
cord-348535-tvs1snq8	2	2	title	title	NN
cord-348535-tvs1snq8	3	1	:	:	:
cord-348535-tvs1snq8	3	2	What	what	WP
cord-348535-tvs1snq8	3	3	is	be	VBZ
cord-348535-tvs1snq8	3	4	the	the	DT
cord-348535-tvs1snq8	3	5	best	good	JJS
cord-348535-tvs1snq8	3	6	drug	drug	NN
cord-348535-tvs1snq8	3	7	to	to	TO
cord-348535-tvs1snq8	3	8	treat	treat	VB
cord-348535-tvs1snq8	3	9	COVID-19	COVID-19	NNP
cord-348535-tvs1snq8	3	10	?	?	.
cord-348535-tvs1snq8	4	1	The	the	DT
cord-348535-tvs1snq8	4	2	need	need	NN
cord-348535-tvs1snq8	4	3	for	for	IN
cord-348535-tvs1snq8	4	4	randomized	randomized	JJ
cord-348535-tvs1snq8	4	5	controlled	control	VBN
cord-348535-tvs1snq8	4	6	trials	trial	NNS
cord-348535-tvs1snq8	4	7	date	date	NN
cord-348535-tvs1snq8	4	8	:	:	:
cord-348535-tvs1snq8	4	9	2020	2020	CD
cord-348535-tvs1snq8	4	10	-	-	HYPH
cord-348535-tvs1snq8	4	11	05	05	CD
cord-348535-tvs1snq8	4	12	-	-	HYPH
cord-348535-tvs1snq8	4	13	19	19	CD
cord-348535-tvs1snq8	4	14	journal	journal	NN
cord-348535-tvs1snq8	4	15	:	:	:
cord-348535-tvs1snq8	4	16	Med	Med	NNP
cord-348535-tvs1snq8	4	17	DOI	DOI	NNP
cord-348535-tvs1snq8	4	18	:	:	:
cord-348535-tvs1snq8	4	19	10.1016	10.1016	CD
cord-348535-tvs1snq8	4	20	/	/	SYM
cord-348535-tvs1snq8	4	21	j.medj.2020.04.002	j.medj.2020.04.002	CD
cord-348535-tvs1snq8	4	22	sha	sha	NNP
cord-348535-tvs1snq8	4	23	:	:	:
cord-348535-tvs1snq8	4	24	0870860be5ab23ff1152be285f7490e638fbf22c	0870860be5ab23ff1152be285f7490e638fbf22c	CD
cord-348535-tvs1snq8	4	25	doc_id	doc_id	CD
cord-348535-tvs1snq8	4	26	:	:	:
cord-348535-tvs1snq8	4	27	348535	348535	CD
cord-348535-tvs1snq8	4	28	cord_uid	cord_uid	NNS
cord-348535-tvs1snq8	4	29	:	:	:
cord-348535-tvs1snq8	4	30	tvs1snq8	tvs1snq8	NNP
cord-348535-tvs1snq8	5	1	The	the	DT
cord-348535-tvs1snq8	5	2	severe	severe	JJ
cord-348535-tvs1snq8	5	3	acute	acute	JJ
cord-348535-tvs1snq8	5	4	respiratory	respiratory	JJ
cord-348535-tvs1snq8	5	5	syndrome	syndrome	NN
cord-348535-tvs1snq8	5	6	coronavirus	coronavirus	NN
cord-348535-tvs1snq8	5	7	2	2	CD
cord-348535-tvs1snq8	6	1	(	(	-LRB-
cord-348535-tvs1snq8	6	2	SARS	SARS	NNP
cord-348535-tvs1snq8	6	3	-	-	HYPH
cord-348535-tvs1snq8	6	4	CoV-2	CoV-2	NNP
cord-348535-tvs1snq8	6	5	)	)	-RRB-
cord-348535-tvs1snq8	6	6	is	be	VBZ
cord-348535-tvs1snq8	6	7	currently	currently	RB
cord-348535-tvs1snq8	6	8	the	the	DT
cord-348535-tvs1snq8	6	9	biggest	big	JJS
cord-348535-tvs1snq8	6	10	public	public	JJ
cord-348535-tvs1snq8	6	11	health	health	NN
cord-348535-tvs1snq8	6	12	challenge	challenge	NN
cord-348535-tvs1snq8	6	13	to	to	IN
cord-348535-tvs1snq8	6	14	the	the	DT
cord-348535-tvs1snq8	6	15	biomedical	biomedical	JJ
cord-348535-tvs1snq8	6	16	community	community	NN
cord-348535-tvs1snq8	6	17	of	of	IN
cord-348535-tvs1snq8	6	18	the	the	DT
cord-348535-tvs1snq8	6	19	last	last	JJ
cord-348535-tvs1snq8	6	20	century	century	NN
cord-348535-tvs1snq8	6	21	.	.	.
cord-348535-tvs1snq8	7	1	Despite	despite	IN
cord-348535-tvs1snq8	7	2	multiple	multiple	JJ
cord-348535-tvs1snq8	7	3	public	public	JJ
cord-348535-tvs1snq8	7	4	health	health	NN
cord-348535-tvs1snq8	7	5	measures,1	measures,1	CD
cord-348535-tvs1snq8	7	6	,	,	,
cord-348535-tvs1snq8	7	7	2	2	CD
cord-348535-tvs1snq8	7	8	,	,	,
cord-348535-tvs1snq8	7	9	3	3	CD
cord-348535-tvs1snq8	7	10	there	there	EX
cord-348535-tvs1snq8	7	11	remains	remain	VBZ
cord-348535-tvs1snq8	7	12	an	an	DT
cord-348535-tvs1snq8	7	13	urgent	urgent	JJ
cord-348535-tvs1snq8	7	14	need	need	NN
cord-348535-tvs1snq8	7	15	for	for	IN
cord-348535-tvs1snq8	7	16	pharmacologic	pharmacologic	JJ
cord-348535-tvs1snq8	7	17	therapies	therapy	NNS
cord-348535-tvs1snq8	7	18	to	to	TO
cord-348535-tvs1snq8	7	19	treat	treat	VB
cord-348535-tvs1snq8	7	20	infected	infected	JJ
cord-348535-tvs1snq8	7	21	patients	patient	NNS
cord-348535-tvs1snq8	7	22	,	,	,
cord-348535-tvs1snq8	7	23	minimize	minimize	VB
cord-348535-tvs1snq8	7	24	mortality	mortality	NN
cord-348535-tvs1snq8	7	25	,	,	,
cord-348535-tvs1snq8	7	26	and	and	CC
cord-348535-tvs1snq8	7	27	decrease	decrease	VB
cord-348535-tvs1snq8	7	28	pressures	pressure	NNS
cord-348535-tvs1snq8	7	29	on	on	IN
cord-348535-tvs1snq8	7	30	intensive	intensive	JJ
cord-348535-tvs1snq8	7	31	care	care	NN
cord-348535-tvs1snq8	7	32	units	unit	NNS
cord-348535-tvs1snq8	7	33	and	and	CC
cord-348535-tvs1snq8	7	34	health	health	NN
cord-348535-tvs1snq8	7	35	systems	system	NNS
cord-348535-tvs1snq8	7	36	and	and	CC
cord-348535-tvs1snq8	7	37	optimally	optimally	RB
cord-348535-tvs1snq8	7	38	,	,	,
cord-348535-tvs1snq8	7	39	they	-PRON-	PRP
cord-348535-tvs1snq8	7	40	should	should	MD
cord-348535-tvs1snq8	7	41	also	also	RB
cord-348535-tvs1snq8	7	42	decrease	decrease	VB
cord-348535-tvs1snq8	7	43	subsequent	subsequent	JJ
cord-348535-tvs1snq8	7	44	transmission	transmission	NN
cord-348535-tvs1snq8	7	45	.	.	.
cord-348535-tvs1snq8	8	1	The	the	DT
cord-348535-tvs1snq8	8	2	severe	severe	JJ
cord-348535-tvs1snq8	8	3	acute	acute	JJ
cord-348535-tvs1snq8	8	4	respiratory	respiratory	JJ
cord-348535-tvs1snq8	8	5	syndrome	syndrome	NN
cord-348535-tvs1snq8	8	6	coronavirus	coronavirus	NN
cord-348535-tvs1snq8	8	7	2	2	CD
cord-348535-tvs1snq8	9	1	(	(	-LRB-
cord-348535-tvs1snq8	9	2	SARS	SARS	NNP
cord-348535-tvs1snq8	9	3	-	-	HYPH
cord-348535-tvs1snq8	9	4	CoV-2	CoV-2	NNP
cord-348535-tvs1snq8	9	5	)	)	-RRB-
cord-348535-tvs1snq8	9	6	is	be	VBZ
cord-348535-tvs1snq8	9	7	currently	currently	RB
cord-348535-tvs1snq8	9	8	the	the	DT
cord-348535-tvs1snq8	9	9	biggest	big	JJS
cord-348535-tvs1snq8	9	10	public	public	JJ
cord-348535-tvs1snq8	9	11	health	health	NN
cord-348535-tvs1snq8	9	12	challenge	challenge	NN
cord-348535-tvs1snq8	9	13	to	to	IN
cord-348535-tvs1snq8	9	14	the	the	DT
cord-348535-tvs1snq8	9	15	biomedical	biomedical	JJ
cord-348535-tvs1snq8	9	16	community	community	NN
cord-348535-tvs1snq8	9	17	of	of	IN
cord-348535-tvs1snq8	9	18	the	the	DT
cord-348535-tvs1snq8	9	19	last	last	JJ
cord-348535-tvs1snq8	9	20	century	century	NN
cord-348535-tvs1snq8	9	21	.	.	.
cord-348535-tvs1snq8	10	1	Despite	despite	IN
cord-348535-tvs1snq8	10	2	multiple	multiple	JJ
cord-348535-tvs1snq8	10	3	public	public	JJ
cord-348535-tvs1snq8	10	4	health	health	NN
cord-348535-tvs1snq8	10	5	measures	measure	NNS
cord-348535-tvs1snq8	10	6	,	,	,
cord-348535-tvs1snq8	10	7	1	1	CD
cord-348535-tvs1snq8	10	8	-	-	SYM
cord-348535-tvs1snq8	10	9	3	3	CD
cord-348535-tvs1snq8	10	10	there	there	EX
cord-348535-tvs1snq8	10	11	remains	remain	VBZ
cord-348535-tvs1snq8	10	12	an	an	DT
cord-348535-tvs1snq8	10	13	urgent	urgent	JJ
cord-348535-tvs1snq8	10	14	need	need	NN
cord-348535-tvs1snq8	10	15	for	for	IN
cord-348535-tvs1snq8	10	16	pharmacologic	pharmacologic	JJ
cord-348535-tvs1snq8	10	17	therapies	therapy	NNS
cord-348535-tvs1snq8	10	18	to	to	TO
cord-348535-tvs1snq8	10	19	treat	treat	VB
cord-348535-tvs1snq8	10	20	infected	infected	JJ
cord-348535-tvs1snq8	10	21	patients	patient	NNS
cord-348535-tvs1snq8	10	22	and	and	CC
cord-348535-tvs1snq8	10	23	minimize	minimize	VB
cord-348535-tvs1snq8	10	24	mortality	mortality	NN
cord-348535-tvs1snq8	10	25	,	,	,
cord-348535-tvs1snq8	10	26	decrease	decrease	VB
cord-348535-tvs1snq8	10	27	pressures	pressure	NNS
cord-348535-tvs1snq8	10	28	on	on	IN
cord-348535-tvs1snq8	10	29	intensive	intensive	JJ
cord-348535-tvs1snq8	10	30	care	care	NN
cord-348535-tvs1snq8	10	31	units	unit	NNS
cord-348535-tvs1snq8	10	32	and	and	CC
cord-348535-tvs1snq8	10	33	health	health	NN
cord-348535-tvs1snq8	10	34	systems	system	NNS
cord-348535-tvs1snq8	10	35	and	and	CC
cord-348535-tvs1snq8	10	36	optimally	optimally	RB
cord-348535-tvs1snq8	10	37	they	-PRON-	PRP
cord-348535-tvs1snq8	10	38	should	should	MD
cord-348535-tvs1snq8	10	39	decrease	decrease	VB
cord-348535-tvs1snq8	10	40	subsequent	subsequent	JJ
cord-348535-tvs1snq8	10	41	transmission	transmission	NN
cord-348535-tvs1snq8	10	42	.	.	.
cord-348535-tvs1snq8	11	1	At	at	IN
cord-348535-tvs1snq8	11	2	the	the	DT
cord-348535-tvs1snq8	11	3	time	time	NN
cord-348535-tvs1snq8	11	4	of	of	IN
cord-348535-tvs1snq8	11	5	writing	writing	NN
cord-348535-tvs1snq8	11	6	,	,	,
cord-348535-tvs1snq8	11	7	there	there	EX
cord-348535-tvs1snq8	11	8	are	be	VBP
cord-348535-tvs1snq8	11	9	no	no	DT
cord-348535-tvs1snq8	11	10	licensed	licensed	JJ
cord-348535-tvs1snq8	11	11	drugs	drug	NNS
cord-348535-tvs1snq8	11	12	to	to	TO
cord-348535-tvs1snq8	11	13	treat	treat	VB
cord-348535-tvs1snq8	11	14	COVID-19	COVID-19	NNP
cord-348535-tvs1snq8	11	15	and	and	CC
cord-348535-tvs1snq8	11	16	a	a	DT
cord-348535-tvs1snq8	11	17	search	search	NN
cord-348535-tvs1snq8	11	18	on	on	IN
cord-348535-tvs1snq8	11	19	clinicaltrials.gov	clinicaltrials.gov	NNP
cord-348535-tvs1snq8	11	20	using	use	VBG
cord-348535-tvs1snq8	11	21	'	'	``
cord-348535-tvs1snq8	11	22	COVID-19	covid-19	NN
cord-348535-tvs1snq8	11	23	'	'	''
cord-348535-tvs1snq8	11	24	as	as	IN
cord-348535-tvs1snq8	11	25	the	the	DT
cord-348535-tvs1snq8	11	26	input	input	NN
cord-348535-tvs1snq8	11	27	term	term	NN
cord-348535-tvs1snq8	11	28	,	,	,
cord-348535-tvs1snq8	11	29	yielded	yield	VBD
cord-348535-tvs1snq8	11	30	657	657	CD
cord-348535-tvs1snq8	11	31	studies	study	NNS
cord-348535-tvs1snq8	11	32	.	.	.
cord-348535-tvs1snq8	12	1	Drug	drug	NN
cord-348535-tvs1snq8	12	2	-	-	HYPH
cord-348535-tvs1snq8	12	3	based	base	VBN
cord-348535-tvs1snq8	12	4	interventions	intervention	NNS
cord-348535-tvs1snq8	12	5	currently	currently	RB
cord-348535-tvs1snq8	12	6	fall	fall	VBP
cord-348535-tvs1snq8	12	7	into	into	IN
cord-348535-tvs1snq8	12	8	categories	category	NNS
cord-348535-tvs1snq8	12	9	including	include	VBG
cord-348535-tvs1snq8	12	10	off	off	RP
cord-348535-tvs1snq8	12	11	label	label	NN
cord-348535-tvs1snq8	12	12	use	use	NN
cord-348535-tvs1snq8	12	13	which	which	WDT
cord-348535-tvs1snq8	12	14	includes	include	VBZ
cord-348535-tvs1snq8	12	15	repurposed	repurpose	VBN
cord-348535-tvs1snq8	12	16	drugs	drug	NNS
cord-348535-tvs1snq8	12	17	,	,	,
cord-348535-tvs1snq8	12	18	4,5	4,5	CD
cord-348535-tvs1snq8	12	19	and	and	CC
cord-348535-tvs1snq8	12	20	newer	new	JJR
cord-348535-tvs1snq8	12	21	entities	entity	NNS
cord-348535-tvs1snq8	12	22	but	but	CC
cord-348535-tvs1snq8	12	23	both	both	DT
cord-348535-tvs1snq8	12	24	categories	category	NNS
cord-348535-tvs1snq8	12	25	should	should	MD
cord-348535-tvs1snq8	12	26	be	be	VB
cord-348535-tvs1snq8	12	27	given	give	VBN
cord-348535-tvs1snq8	12	28	in	in	IN
cord-348535-tvs1snq8	12	29	the	the	DT
cord-348535-tvs1snq8	12	30	context	context	NN
cord-348535-tvs1snq8	12	31	of	of	IN
cord-348535-tvs1snq8	12	32	clinical	clinical	JJ
cord-348535-tvs1snq8	12	33	trials	trial	NNS
cord-348535-tvs1snq8	12	34	.	.	.
cord-348535-tvs1snq8	13	1	In	in	IN
cord-348535-tvs1snq8	13	2	Wuhan	Wuhan	NNP
cord-348535-tvs1snq8	13	3	,	,	,
cord-348535-tvs1snq8	13	4	China	China	NNP
cord-348535-tvs1snq8	13	5	,	,	,
cord-348535-tvs1snq8	13	6	then	then	RB
cord-348535-tvs1snq8	13	7	the	the	DT
cord-348535-tvs1snq8	13	8	epicentre	epicentre	NN
cord-348535-tvs1snq8	13	9	of	of	IN
cord-348535-tvs1snq8	13	10	the	the	DT
cord-348535-tvs1snq8	13	11	pandemic	pandemic	NN
cord-348535-tvs1snq8	13	12	,	,	,
cord-348535-tvs1snq8	13	13	Cao	Cao	NNP
cord-348535-tvs1snq8	13	14	et	et	NNP
cord-348535-tvs1snq8	13	15	al	al	NNP
cord-348535-tvs1snq8	13	16	.	.	.
cord-348535-tvs1snq8	14	1	under	under	IN
cord-348535-tvs1snq8	14	2	heroic	heroic	JJ
cord-348535-tvs1snq8	14	3	circumstances	circumstance	NNS
cord-348535-tvs1snq8	14	4	,	,	,
cord-348535-tvs1snq8	14	5	conducted	conduct	VBD
cord-348535-tvs1snq8	14	6	a	a	DT
cord-348535-tvs1snq8	14	7	randomized	randomize	VBN
cord-348535-tvs1snq8	14	8	,	,	,
cord-348535-tvs1snq8	14	9	controlled	control	VBN
cord-348535-tvs1snq8	14	10	,	,	,
cord-348535-tvs1snq8	14	11	open	open	JJ
cord-348535-tvs1snq8	14	12	-	-	HYPH
cord-348535-tvs1snq8	14	13	label	label	NN
cord-348535-tvs1snq8	14	14	trial	trial	NN
cord-348535-tvs1snq8	14	15	involving	involve	VBG
cord-348535-tvs1snq8	14	16	199	199	CD
cord-348535-tvs1snq8	14	17	hospitalized	hospitalize	VBN
cord-348535-tvs1snq8	14	18	patients	patient	NNS
cord-348535-tvs1snq8	14	19	with	with	IN
cord-348535-tvs1snq8	14	20	confirmed	confirm	VBN
cord-348535-tvs1snq8	14	21	SARS	SARS	NNP
cord-348535-tvs1snq8	14	22	-	-	HYPH
cord-348535-tvs1snq8	14	23	CoV-2	CoV-2	NNP
cord-348535-tvs1snq8	14	24	infection	infection	NN
cord-348535-tvs1snq8	14	25	including	include	VBG
cord-348535-tvs1snq8	14	26	as	as	IN
cord-348535-tvs1snq8	14	27	an	an	DT
cord-348535-tvs1snq8	14	28	entry	entry	NN
cord-348535-tvs1snq8	14	29	criteria	criteria	VBZ
cord-348535-tvs1snq8	14	30	oxygen	oxygen	NN
cord-348535-tvs1snq8	14	31	saturation	saturation	NN
cord-348535-tvs1snq8	14	32	(	(	-LRB-
cord-348535-tvs1snq8	14	33	SaO2	SaO2	NNS
cord-348535-tvs1snq8	14	34	)	)	-RRB-
cord-348535-tvs1snq8	14	35	of	of	IN
cord-348535-tvs1snq8	14	36	94	94	CD
cord-348535-tvs1snq8	14	37	%	%	NN
cord-348535-tvs1snq8	14	38	or	or	CC
cord-348535-tvs1snq8	14	39	less	less	JJR
cord-348535-tvs1snq8	14	40	on	on	IN
cord-348535-tvs1snq8	14	41	air	air	NN
cord-348535-tvs1snq8	14	42	(	(	-LRB-
cord-348535-tvs1snq8	14	43	ChiCTR2000029308	ChiCTR2000029308	NNP
cord-348535-tvs1snq8	14	44	)	)	-RRB-
cord-348535-tvs1snq8	14	45	.	.	.
cord-348535-tvs1snq8	15	1	Patients	patient	NNS
cord-348535-tvs1snq8	15	2	were	be	VBD
cord-348535-tvs1snq8	15	3	randomly	randomly	RB
cord-348535-tvs1snq8	15	4	assigned	assign	VBN
cord-348535-tvs1snq8	15	5	1:1	1:1	CD
cord-348535-tvs1snq8	15	6	to	to	TO
cord-348535-tvs1snq8	15	7	receive	receive	VB
cord-348535-tvs1snq8	15	8	either	either	DT
cord-348535-tvs1snq8	15	9	lopinavir	lopinavir	NNS
cord-348535-tvs1snq8	15	10	-	-	HYPH
cord-348535-tvs1snq8	15	11	ritonavir	ritonavir	NNP
cord-348535-tvs1snq8	15	12	(	(	-LRB-
cord-348535-tvs1snq8	15	13	400	400	CD
cord-348535-tvs1snq8	15	14	mg	mg	NN
cord-348535-tvs1snq8	15	15	and	and	CC
cord-348535-tvs1snq8	15	16	100	100	CD
cord-348535-tvs1snq8	15	17	mg	mg	NNS
cord-348535-tvs1snq8	15	18	,	,	,
cord-348535-tvs1snq8	15	19	respectively	respectively	RB
cord-348535-tvs1snq8	15	20	)	)	-RRB-
cord-348535-tvs1snq8	15	21	twice	twice	RB
cord-348535-tvs1snq8	15	22	daily	daily	RB
cord-348535-tvs1snq8	15	23	for	for	IN
cord-348535-tvs1snq8	15	24	14	14	CD
cord-348535-tvs1snq8	15	25	days	day	NNS
cord-348535-tvs1snq8	15	26	,	,	,
cord-348535-tvs1snq8	15	27	or	or	CC
cord-348535-tvs1snq8	15	28	standard	standard	JJ
cord-348535-tvs1snq8	15	29	care	care	NN
cord-348535-tvs1snq8	15	30	alone	alone	RB
cord-348535-tvs1snq8	15	31	.	.	.
cord-348535-tvs1snq8	16	1	The	the	DT
cord-348535-tvs1snq8	16	2	primary	primary	JJ
cord-348535-tvs1snq8	16	3	end	end	NN
cord-348535-tvs1snq8	16	4	point	point	NN
cord-348535-tvs1snq8	16	5	was	be	VBD
cord-348535-tvs1snq8	16	6	the	the	DT
cord-348535-tvs1snq8	16	7	time	time	NN
cord-348535-tvs1snq8	16	8	to	to	IN
cord-348535-tvs1snq8	16	9	clinical	clinical	JJ
cord-348535-tvs1snq8	16	10	improvement	improvement	NN
cord-348535-tvs1snq8	16	11	,	,	,
cord-348535-tvs1snq8	16	12	defined	define	VBN
cord-348535-tvs1snq8	16	13	as	as	IN
cord-348535-tvs1snq8	16	14	the	the	DT
cord-348535-tvs1snq8	16	15	time	time	NN
cord-348535-tvs1snq8	16	16	from	from	IN
cord-348535-tvs1snq8	16	17	randomization	randomization	NN
cord-348535-tvs1snq8	16	18	to	to	IN
cord-348535-tvs1snq8	16	19	either	either	CC
cord-348535-tvs1snq8	16	20	an	an	DT
cord-348535-tvs1snq8	16	21	improvement	improvement	NN
cord-348535-tvs1snq8	16	22	of	of	IN
cord-348535-tvs1snq8	16	23	two	two	CD
cord-348535-tvs1snq8	16	24	points	point	NNS
cord-348535-tvs1snq8	16	25	on	on	IN
cord-348535-tvs1snq8	16	26	a	a	DT
cord-348535-tvs1snq8	16	27	seven	seven	CD
cord-348535-tvs1snq8	16	28	-	-	HYPH
cord-348535-tvs1snq8	16	29	category	category	NN
cord-348535-tvs1snq8	16	30	ordinal	ordinal	JJ
cord-348535-tvs1snq8	16	31	scale	scale	NN
cord-348535-tvs1snq8	16	32	or	or	CC
cord-348535-tvs1snq8	16	33	discharge	discharge	NN
cord-348535-tvs1snq8	16	34	from	from	IN
cord-348535-tvs1snq8	16	35	the	the	DT
cord-348535-tvs1snq8	16	36	hospital	hospital	NN
cord-348535-tvs1snq8	16	37	,	,	,
cord-348535-tvs1snq8	16	38	whichever	whichever	WDT
cord-348535-tvs1snq8	16	39	came	come	VBD
cord-348535-tvs1snq8	16	40	first	first	RB
cord-348535-tvs1snq8	16	41	.	.	.
cord-348535-tvs1snq8	17	1	6	6	CD
cord-348535-tvs1snq8	18	1	Even	even	RB
cord-348535-tvs1snq8	18	2	though	though	IN
cord-348535-tvs1snq8	18	3	their	-PRON-	PRP$
cord-348535-tvs1snq8	18	4	study	study	NN
cord-348535-tvs1snq8	18	5	showed	show	VBD
cord-348535-tvs1snq8	18	6	no	no	DT
cord-348535-tvs1snq8	18	7	benefits	benefit	NNS
cord-348535-tvs1snq8	18	8	with	with	IN
cord-348535-tvs1snq8	18	9	lopinavir	lopinavir	NNS
cord-348535-tvs1snq8	18	10	-	-	HYPH
cord-348535-tvs1snq8	18	11	ritonavir	ritonavir	NNP
cord-348535-tvs1snq8	18	12	treatment	treatment	NN
cord-348535-tvs1snq8	18	13	beyond	beyond	IN
cord-348535-tvs1snq8	18	14	standard	standard	JJ
cord-348535-tvs1snq8	18	15	care	care	NN
cord-348535-tvs1snq8	18	16	,	,	,
cord-348535-tvs1snq8	18	17	this	this	DT
cord-348535-tvs1snq8	18	18	is	be	VBZ
cord-348535-tvs1snq8	18	19	exactly	exactly	RB
cord-348535-tvs1snq8	18	20	the	the	DT
cord-348535-tvs1snq8	18	21	sort	sort	NN
cord-348535-tvs1snq8	18	22	of	of	IN
cord-348535-tvs1snq8	18	23	study	study	NN
cord-348535-tvs1snq8	18	24	that	that	IN
cord-348535-tvs1snq8	18	25	best	well	RBS
cord-348535-tvs1snq8	18	26	informs	inform	VBZ
cord-348535-tvs1snq8	18	27	our	-PRON-	PRP$
cord-348535-tvs1snq8	18	28	treatment	treatment	NN
cord-348535-tvs1snq8	18	29	options	option	NNS
cord-348535-tvs1snq8	18	30	.	.	.
cord-348535-tvs1snq8	19	1	Following	follow	VBG
cord-348535-tvs1snq8	19	2	this	this	DT
cord-348535-tvs1snq8	19	3	,	,	,
cord-348535-tvs1snq8	19	4	we	-PRON-	PRP
cord-348535-tvs1snq8	19	5	were	be	VBD
cord-348535-tvs1snq8	19	6	surprised	surprised	JJ
cord-348535-tvs1snq8	19	7	to	to	TO
cord-348535-tvs1snq8	19	8	see	see	VB
cord-348535-tvs1snq8	19	9	the	the	DT
cord-348535-tvs1snq8	19	10	New	New	NNP
cord-348535-tvs1snq8	19	11	England	England	NNP
cord-348535-tvs1snq8	19	12	Journal	Journal	NNP
cord-348535-tvs1snq8	19	13	of	of	IN
cord-348535-tvs1snq8	19	14	Medicine	Medicine	NNP
cord-348535-tvs1snq8	19	15	publishing	publish	VBG
cord-348535-tvs1snq8	19	16	a	a	DT
cord-348535-tvs1snq8	19	17	single	single	JJ
cord-348535-tvs1snq8	19	18	arm	arm	NN
cord-348535-tvs1snq8	19	19	study	study	NN
cord-348535-tvs1snq8	19	20	on	on	IN
cord-348535-tvs1snq8	19	21	61	61	CD
cord-348535-tvs1snq8	19	22	patients	patient	NNS
cord-348535-tvs1snq8	19	23	who	who	WP
cord-348535-tvs1snq8	19	24	received	receive	VBD
cord-348535-tvs1snq8	19	25	at	at	IN
cord-348535-tvs1snq8	19	26	least	least	RBS
cord-348535-tvs1snq8	19	27	one	one	CD
cord-348535-tvs1snq8	19	28	dose	dose	NN
cord-348535-tvs1snq8	19	29	of	of	IN
cord-348535-tvs1snq8	19	30	remdesevir	remdesevir	NNS
cord-348535-tvs1snq8	19	31	,	,	,
cord-348535-tvs1snq8	19	32	again	again	RB
cord-348535-tvs1snq8	19	33	with	with	IN
cord-348535-tvs1snq8	19	34	similar	similar	JJ
cord-348535-tvs1snq8	19	35	entry	entry	NN
cord-348535-tvs1snq8	19	36	criteria	criterion	NNS
cord-348535-tvs1snq8	19	37	of	of	IN
cord-348535-tvs1snq8	19	38	SaO2	SaO2	NNS
cord-348535-tvs1snq8	19	39	<	<	XX
cord-348535-tvs1snq8	19	40	94	94	CD
cord-348535-tvs1snq8	19	41	%	%	NN
cord-348535-tvs1snq8	19	42	on	on	IN
cord-348535-tvs1snq8	19	43	air	air	NN
cord-348535-tvs1snq8	19	44	.	.	.
cord-348535-tvs1snq8	20	1	7	7	CD
cord-348535-tvs1snq8	20	2	 	 	_SP
cord-348535-tvs1snq8	21	1	One	one	PRP
cord-348535-tvs1snq8	21	2	presumes	presume	VBZ
cord-348535-tvs1snq8	21	3	that	that	IN
cord-348535-tvs1snq8	21	4	the	the	DT
cord-348535-tvs1snq8	21	5	patients	patient	NNS
cord-348535-tvs1snq8	21	6	in	in	IN
cord-348535-tvs1snq8	21	7	the	the	DT
cord-348535-tvs1snq8	21	8	remdesevir	remdesevir	NNP
cord-348535-tvs1snq8	21	9	single	single	JJ
cord-348535-tvs1snq8	21	10	arm	arm	NN
cord-348535-tvs1snq8	21	11	study	study	NN
cord-348535-tvs1snq8	21	12	,	,	,
cord-348535-tvs1snq8	21	13	and	and	CC
cord-348535-tvs1snq8	21	14	several	several	JJ
cord-348535-tvs1snq8	21	15	included	include	VBN
cord-348535-tvs1snq8	21	16	in	in	IN
cord-348535-tvs1snq8	21	17	an	an	DT
cord-348535-tvs1snq8	21	18	earlier	early	JJR
cord-348535-tvs1snq8	21	19	Lancet	Lancet	NNP
cord-348535-tvs1snq8	21	20	paper	paper	NN
cord-348535-tvs1snq8	21	21	,	,	,
cord-348535-tvs1snq8	21	22	8	8	CD
cord-348535-tvs1snq8	21	23	were	be	VBD
cord-348535-tvs1snq8	21	24	recruited	recruit	VBN
cord-348535-tvs1snq8	21	25	in	in	IN
cord-348535-tvs1snq8	21	26	perhaps	perhaps	RB
cord-348535-tvs1snq8	21	27	easier	easy	JJR
cord-348535-tvs1snq8	21	28	conditions	condition	NNS
cord-348535-tvs1snq8	21	29	than	than	IN
cord-348535-tvs1snq8	21	30	those	those	DT
cord-348535-tvs1snq8	21	31	in	in	IN
cord-348535-tvs1snq8	21	32	Wuhan	Wuhan	NNP
cord-348535-tvs1snq8	21	33	earlier	early	RBR
cord-348535-tvs1snq8	21	34	this	this	DT
cord-348535-tvs1snq8	21	35	year	year	NN
cord-348535-tvs1snq8	21	36	.	.	.
cord-348535-tvs1snq8	22	1	Randomised	randomised	JJ
cord-348535-tvs1snq8	22	2	trials	trial	NNS
cord-348535-tvs1snq8	22	3	are	be	VBP
cord-348535-tvs1snq8	22	4	designed	design	VBN
cord-348535-tvs1snq8	22	5	to	to	TO
cord-348535-tvs1snq8	22	6	precisely	precisely	RB
cord-348535-tvs1snq8	22	7	answer	answer	VB
cord-348535-tvs1snq8	22	8	questions	question	NNS
cord-348535-tvs1snq8	22	9	regarding	regard	VBG
cord-348535-tvs1snq8	22	10	toxicity	toxicity	NN
cord-348535-tvs1snq8	22	11	and	and	CC
cord-348535-tvs1snq8	22	12	efficacy	efficacy	NN
cord-348535-tvs1snq8	22	13	beyond	beyond	IN
cord-348535-tvs1snq8	22	14	standard	standard	NN
cord-348535-tvs1snq8	22	15	of	of	IN
cord-348535-tvs1snq8	22	16	care	care	NN
cord-348535-tvs1snq8	22	17	and	and	CC
cord-348535-tvs1snq8	22	18	in	in	IN
cord-348535-tvs1snq8	22	19	the	the	DT
cord-348535-tvs1snq8	22	20	absence	absence	NN
cord-348535-tvs1snq8	22	21	of	of	IN
cord-348535-tvs1snq8	22	22	an	an	DT
cord-348535-tvs1snq8	22	23	effective	effective	JJ
cord-348535-tvs1snq8	22	24	therapy	therapy	NN
cord-348535-tvs1snq8	22	25	it	-PRON-	PRP
cord-348535-tvs1snq8	22	26	remains	remain	VBZ
cord-348535-tvs1snq8	22	27	entirely	entirely	RB
cord-348535-tvs1snq8	22	28	reasonable	reasonable	JJ
cord-348535-tvs1snq8	22	29	and	and	CC
cord-348535-tvs1snq8	22	30	ethical	ethical	JJ
cord-348535-tvs1snq8	22	31	at	at	IN
cord-348535-tvs1snq8	22	32	this	this	DT
cord-348535-tvs1snq8	22	33	point	point	NN
cord-348535-tvs1snq8	22	34	to	to	TO
cord-348535-tvs1snq8	22	35	perform	perform	VB
cord-348535-tvs1snq8	22	36	a	a	DT
cord-348535-tvs1snq8	22	37	trial	trial	NN
cord-348535-tvs1snq8	22	38	versus	versus	IN
cord-348535-tvs1snq8	22	39	placebo	placebo	NN
cord-348535-tvs1snq8	22	40	.	.	.
cord-348535-tvs1snq8	23	1	They	-PRON-	PRP
cord-348535-tvs1snq8	23	2	are	be	VBP
cord-348535-tvs1snq8	23	3	much	much	RB
cord-348535-tvs1snq8	23	4	more	more	RBR
cord-348535-tvs1snq8	23	5	informative	informative	JJ
cord-348535-tvs1snq8	23	6	than	than	IN
cord-348535-tvs1snq8	23	7	single	single	JJ
cord-348535-tvs1snq8	23	8	arm	arm	NN
cord-348535-tvs1snq8	23	9	studies	study	NNS
cord-348535-tvs1snq8	23	10	which	which	WDT
cord-348535-tvs1snq8	23	11	result	result	VBP
cord-348535-tvs1snq8	23	12	in	in	IN
cord-348535-tvs1snq8	23	13	claims	claim	NNS
cord-348535-tvs1snq8	23	14	,	,	,
cord-348535-tvs1snq8	23	15	perhaps	perhaps	RB
cord-348535-tvs1snq8	23	16	borne	bear	VBN
cord-348535-tvs1snq8	23	17	from	from	IN
cord-348535-tvs1snq8	23	18	hope	hope	NN
cord-348535-tvs1snq8	23	19	and/or	and/or	CC
cord-348535-tvs1snq8	23	20	desperation	desperation	NN
cord-348535-tvs1snq8	23	21	,	,	,
cord-348535-tvs1snq8	23	22	that	that	IN
cord-348535-tvs1snq8	23	23	drugs	drug	NNS
cord-348535-tvs1snq8	23	24	work	work	VBP
cord-348535-tvs1snq8	23	25	,	,	,
cord-348535-tvs1snq8	23	26	9	9	CD
cord-348535-tvs1snq8	23	27	and	and	CC
cord-348535-tvs1snq8	23	28	such	such	JJ
cord-348535-tvs1snq8	23	29	claims	claim	NNS
cord-348535-tvs1snq8	23	30	include	include	VBP
cord-348535-tvs1snq8	23	31	those	those	DT
cord-348535-tvs1snq8	23	32	from	from	IN
cord-348535-tvs1snq8	23	33	physicians	physician	NNS
cord-348535-tvs1snq8	23	34	stating	state	VBG
cord-348535-tvs1snq8	23	35	very	very	RB
cord-348535-tvs1snq8	23	36	high	high	JJ
cord-348535-tvs1snq8	23	37	cure	cure	NN
cord-348535-tvs1snq8	23	38	rates	rate	NNS
cord-348535-tvs1snq8	23	39	.	.	.
cord-348535-tvs1snq8	24	1	Clearly	clearly	RB
cord-348535-tvs1snq8	24	2	,	,	,
cord-348535-tvs1snq8	24	3	recruiting	recruit	VBG
cord-348535-tvs1snq8	24	4	patients	patient	NNS
cord-348535-tvs1snq8	24	5	recently	recently	RB
cord-348535-tvs1snq8	24	6	diagnosed	diagnose	VBN
cord-348535-tvs1snq8	24	7	will	will	MD
cord-348535-tvs1snq8	24	8	have	have	VB
cord-348535-tvs1snq8	24	9	'	'	``
cord-348535-tvs1snq8	24	10	cure	cure	NN
cord-348535-tvs1snq8	24	11	rates	rate	NNS
cord-348535-tvs1snq8	24	12	'	'	''
cord-348535-tvs1snq8	24	13	usually	usually	RB
cord-348535-tvs1snq8	24	14	in	in	IN
cord-348535-tvs1snq8	24	15	the	the	DT
cord-348535-tvs1snq8	24	16	high	high	JJ
cord-348535-tvs1snq8	24	17	90s%	90s%	CD
cord-348535-tvs1snq8	24	18	,	,	,
cord-348535-tvs1snq8	24	19	unless	unless	IN
cord-348535-tvs1snq8	24	20	one	one	CD
cord-348535-tvs1snq8	24	21	focuses	focus	VBZ
cord-348535-tvs1snq8	24	22	on	on	IN
cord-348535-tvs1snq8	24	23	recruiting	recruit	VBG
cord-348535-tvs1snq8	24	24	hospitalised	hospitalise	VBN
cord-348535-tvs1snq8	24	25	patients	patient	NNS
cord-348535-tvs1snq8	24	26	and/or	and/or	CC
cord-348535-tvs1snq8	24	27	the	the	DT
cord-348535-tvs1snq8	24	28	elderly	elderly	JJ
cord-348535-tvs1snq8	24	29	,	,	,
cord-348535-tvs1snq8	24	30	frail	frail	JJ
cord-348535-tvs1snq8	24	31	,	,	,
cord-348535-tvs1snq8	24	32	those	those	DT
cord-348535-tvs1snq8	24	33	with	with	IN
cord-348535-tvs1snq8	24	34	co	co	NNS
cord-348535-tvs1snq8	24	35	-	-	NNS
cord-348535-tvs1snq8	24	36	morbidities	morbidity	NNS
cord-348535-tvs1snq8	24	37	or	or	CC
cord-348535-tvs1snq8	24	38	a	a	DT
cord-348535-tvs1snq8	24	39	high	high	JJ
cord-348535-tvs1snq8	24	40	body	body	NN
cord-348535-tvs1snq8	24	41	mass	mass	NN
cord-348535-tvs1snq8	24	42	index	index	NN
cord-348535-tvs1snq8	24	43	,	,	,
cord-348535-tvs1snq8	24	44	to	to	TO
cord-348535-tvs1snq8	24	45	name	name	VB
cord-348535-tvs1snq8	24	46	a	a	DT
cord-348535-tvs1snq8	24	47	few	few	JJ
cord-348535-tvs1snq8	24	48	examples	example	NNS
cord-348535-tvs1snq8	24	49	.	.	.
cord-348535-tvs1snq8	25	1	A	a	DT
cord-348535-tvs1snq8	25	2	well	well	RB
cord-348535-tvs1snq8	25	3	-	-	HYPH
cord-348535-tvs1snq8	25	4	known	know	VBN
cord-348535-tvs1snq8	25	5	French	french	JJ
cord-348535-tvs1snq8	25	6	microbiologist	microbiologist	NN
cord-348535-tvs1snq8	25	7	on	on	IN
cord-348535-tvs1snq8	25	8	social	social	JJ
cord-348535-tvs1snq8	25	9	media	medium	NNS
cord-348535-tvs1snq8	25	10	has	have	VBZ
cord-348535-tvs1snq8	25	11	promoted	promote	VBN
cord-348535-tvs1snq8	25	12	the	the	DT
cord-348535-tvs1snq8	25	13	use	use	NN
cord-348535-tvs1snq8	25	14	of	of	IN
cord-348535-tvs1snq8	25	15	chloroquine	chloroquine	NN
cord-348535-tvs1snq8	25	16	to	to	TO
cord-348535-tvs1snq8	25	17	treat	treat	VB
cord-348535-tvs1snq8	25	18	or	or	CC
cord-348535-tvs1snq8	25	19	prevent	prevent	VB
cord-348535-tvs1snq8	25	20	COVID-19	covid-19	CD
cord-348535-tvs1snq8	25	21	.	.	.
cord-348535-tvs1snq8	26	1	The	the	DT
cord-348535-tvs1snq8	26	2	FDA	FDA	NNP
cord-348535-tvs1snq8	26	3	has	have	VBZ
cord-348535-tvs1snq8	26	4	approved	approve	VBN
cord-348535-tvs1snq8	26	5	it	-PRON-	PRP
cord-348535-tvs1snq8	26	6	,	,	,
cord-348535-tvs1snq8	26	7	although	although	IN
cord-348535-tvs1snq8	26	8	at	at	IN
cord-348535-tvs1snq8	26	9	the	the	DT
cord-348535-tvs1snq8	26	10	time	time	NN
cord-348535-tvs1snq8	26	11	of	of	IN
cord-348535-tvs1snq8	26	12	writing	writing	NN
cord-348535-tvs1snq8	26	13	they	-PRON-	PRP
cord-348535-tvs1snq8	26	14	have	have	VBP
cord-348535-tvs1snq8	26	15	n't	not	RB
cord-348535-tvs1snq8	26	16	explained	explain	VBN
cord-348535-tvs1snq8	26	17	the	the	DT
cord-348535-tvs1snq8	26	18	rationale	rationale	NN
cord-348535-tvs1snq8	26	19	behind	behind	IN
cord-348535-tvs1snq8	26	20	the	the	DT
cord-348535-tvs1snq8	26	21	approval	approval	NN
cord-348535-tvs1snq8	26	22	,	,	,
cord-348535-tvs1snq8	26	23	and	and	CC
cord-348535-tvs1snq8	26	24	as	as	IN
cord-348535-tvs1snq8	26	25	a	a	DT
cord-348535-tvs1snq8	26	26	consequence	consequence	NN
cord-348535-tvs1snq8	26	27	patients	patient	NNS
cord-348535-tvs1snq8	26	28	,	,	,
cord-348535-tvs1snq8	26	29	institutions	institution	NNS
cord-348535-tvs1snq8	26	30	and	and	CC
cord-348535-tvs1snq8	26	31	the	the	DT
cord-348535-tvs1snq8	26	32	worried	worried	JJ
cord-348535-tvs1snq8	26	33	public	public	NN
cord-348535-tvs1snq8	26	34	have	have	VBP
cord-348535-tvs1snq8	26	35	demanded	demand	VBN
cord-348535-tvs1snq8	26	36	immediate	immediate	JJ
cord-348535-tvs1snq8	26	37	chloroquine	chloroquine	NN
cord-348535-tvs1snq8	26	38	for	for	IN
cord-348535-tvs1snq8	26	39	all	all	DT
cord-348535-tvs1snq8	26	40	.	.	.
cord-348535-tvs1snq8	27	1	The	the	DT
cord-348535-tvs1snq8	27	2	resulting	result	VBG
cord-348535-tvs1snq8	27	3	rush	rush	NN
cord-348535-tvs1snq8	27	4	on	on	IN
cord-348535-tvs1snq8	27	5	chloroquine	chloroquine	NN
cord-348535-tvs1snq8	27	6	has	have	VBZ
cord-348535-tvs1snq8	27	7	led	lead	VBN
cord-348535-tvs1snq8	27	8	to	to	IN
cord-348535-tvs1snq8	27	9	severe	severe	JJ
cord-348535-tvs1snq8	27	10	shortages	shortage	NNS
cord-348535-tvs1snq8	27	11	of	of	IN
cord-348535-tvs1snq8	27	12	the	the	DT
cord-348535-tvs1snq8	27	13	drug	drug	NN
cord-348535-tvs1snq8	27	14	,	,	,
cord-348535-tvs1snq8	27	15	and	and	CC
cord-348535-tvs1snq8	27	16	patients	patient	NNS
cord-348535-tvs1snq8	27	17	taking	take	VBG
cord-348535-tvs1snq8	27	18	regular	regular	JJ
cord-348535-tvs1snq8	27	19	chloroquine	chloroquine	NN
cord-348535-tvs1snq8	27	20	or	or	CC
cord-348535-tvs1snq8	27	21	hydroxychloroquine	hydroxychloroquine	NN
cord-348535-tvs1snq8	27	22	for	for	IN
cord-348535-tvs1snq8	27	23	lupus	lupus	NN
cord-348535-tvs1snq8	27	24	or	or	CC
cord-348535-tvs1snq8	27	25	other	other	JJ
cord-348535-tvs1snq8	27	26	systemic	systemic	JJ
cord-348535-tvs1snq8	27	27	diseases	disease	NNS
cord-348535-tvs1snq8	27	28	had	have	VBD
cord-348535-tvs1snq8	27	29	to	to	TO
cord-348535-tvs1snq8	27	30	stop	stop	VB
cord-348535-tvs1snq8	27	31	their	-PRON-	PRP$
cord-348535-tvs1snq8	27	32	treatment	treatment	NN
cord-348535-tvs1snq8	27	33	due	due	IN
cord-348535-tvs1snq8	27	34	to	to	IN
cord-348535-tvs1snq8	27	35	a	a	DT
cord-348535-tvs1snq8	27	36	lack	lack	NN
cord-348535-tvs1snq8	27	37	of	of	IN
cord-348535-tvs1snq8	27	38	supply	supply	NN
cord-348535-tvs1snq8	27	39	.	.	.
cord-348535-tvs1snq8	28	1	This	this	DT
cord-348535-tvs1snq8	28	2	drug	drug	NN
cord-348535-tvs1snq8	28	3	has	have	VBZ
cord-348535-tvs1snq8	28	4	well	well	RB
cord-348535-tvs1snq8	28	5	known	know	VBN
cord-348535-tvs1snq8	28	6	often	often	RB
cord-348535-tvs1snq8	28	7	serious	serious	JJ
cord-348535-tvs1snq8	28	8	toxicities	toxicity	NNS
cord-348535-tvs1snq8	28	9	;	;	:
cord-348535-tvs1snq8	28	10	10	10	CD
cord-348535-tvs1snq8	28	11	we	-PRON-	PRP
cord-348535-tvs1snq8	28	12	note	note	VBP
cord-348535-tvs1snq8	28	13	one	one	CD
cord-348535-tvs1snq8	28	14	small	small	JJ
cord-348535-tvs1snq8	28	15	study	study	NN
cord-348535-tvs1snq8	28	16	was	be	VBD
cord-348535-tvs1snq8	28	17	stopped	stop	VBN
cord-348535-tvs1snq8	28	18	due	due	JJ
cord-348535-tvs1snq8	28	19	to	to	IN
cord-348535-tvs1snq8	28	20	potential	potential	JJ
cord-348535-tvs1snq8	28	21	cardiac	cardiac	JJ
cord-348535-tvs1snq8	28	22	complications	complication	NNS
cord-348535-tvs1snq8	28	23	(	(	-LRB-
cord-348535-tvs1snq8	28	24	https://www.nytimes.com/2020/04/12/health/chloroquine-coronavirus-trump.html	https://www.nytimes.com/2020/04/12/health/chloroquine-coronavirus-trump.html	NNP
cord-348535-tvs1snq8	28	25	)	)	-RRB-
cord-348535-tvs1snq8	28	26	and	and	CC
cord-348535-tvs1snq8	28	27	we	-PRON-	PRP
cord-348535-tvs1snq8	28	28	suggest	suggest	VBP
cord-348535-tvs1snq8	28	29	it	-PRON-	PRP
cord-348535-tvs1snq8	28	30	should	should	MD
cord-348535-tvs1snq8	28	31	only	only	RB
cord-348535-tvs1snq8	28	32	be	be	VB
cord-348535-tvs1snq8	28	33	taken	take	VBN
cord-348535-tvs1snq8	28	34	in	in	IN
cord-348535-tvs1snq8	28	35	the	the	DT
cord-348535-tvs1snq8	28	36	context	context	NN
cord-348535-tvs1snq8	28	37	of	of	IN
cord-348535-tvs1snq8	28	38	a	a	DT
cord-348535-tvs1snq8	28	39	randomised	randomised	JJ
cord-348535-tvs1snq8	28	40	or	or	CC
cord-348535-tvs1snq8	28	41	other	other	JJ
cord-348535-tvs1snq8	28	42	clinical	clinical	JJ
cord-348535-tvs1snq8	28	43	study	study	NN
cord-348535-tvs1snq8	28	44	.	.	.
cord-348535-tvs1snq8	29	1	This	this	DT
cord-348535-tvs1snq8	29	2	is	be	VBZ
cord-348535-tvs1snq8	29	3	not	not	RB
cord-348535-tvs1snq8	29	4	to	to	TO
cord-348535-tvs1snq8	29	5	suggest	suggest	VB
cord-348535-tvs1snq8	29	6	single	single	JJ
cord-348535-tvs1snq8	29	7	arm	arm	NN
cord-348535-tvs1snq8	29	8	studies	study	NNS
cord-348535-tvs1snq8	29	9	are	be	VBP
cord-348535-tvs1snq8	29	10	not	not	RB
cord-348535-tvs1snq8	29	11	helpful	helpful	JJ
cord-348535-tvs1snq8	29	12	:	:	:
cord-348535-tvs1snq8	29	13	they	-PRON-	PRP
cord-348535-tvs1snq8	29	14	inform	inform	VBP
cord-348535-tvs1snq8	29	15	subsequent	subsequent	JJ
cord-348535-tvs1snq8	29	16	trials	trial	NNS
cord-348535-tvs1snq8	29	17	including	include	VBG
cord-348535-tvs1snq8	29	18	dosage	dosage	NN
cord-348535-tvs1snq8	29	19	,	,	,
cord-348535-tvs1snq8	29	20	duration	duration	NN
cord-348535-tvs1snq8	29	21	and	and	CC
cord-348535-tvs1snq8	29	22	appropriate	appropriate	JJ
cord-348535-tvs1snq8	29	23	endpoints	endpoint	NNS
cord-348535-tvs1snq8	29	24	.	.	.
cord-348535-tvs1snq8	30	1	For	for	IN
cord-348535-tvs1snq8	30	2	example	example	NN
cord-348535-tvs1snq8	30	3	,	,	,
cord-348535-tvs1snq8	30	4	we	-PRON-	PRP
cord-348535-tvs1snq8	30	5	have	have	VBP
cord-348535-tvs1snq8	30	6	observed	observe	VBN
cord-348535-tvs1snq8	30	7	11	11	CD
cord-348535-tvs1snq8	30	8	that	that	IN
cord-348535-tvs1snq8	30	9	use	use	NN
cord-348535-tvs1snq8	30	10	of	of	IN
cord-348535-tvs1snq8	30	11	baricitinib	baricitinib	NN
cord-348535-tvs1snq8	30	12	for	for	IN
cord-348535-tvs1snq8	30	13	10	10	CD
cord-348535-tvs1snq8	30	14	days	day	NNS
cord-348535-tvs1snq8	30	15	is	be	VBZ
cord-348535-tvs1snq8	30	16	associated	associate	VBN
cord-348535-tvs1snq8	30	17	with	with	IN
cord-348535-tvs1snq8	30	18	viral	viral	JJ
cord-348535-tvs1snq8	30	19	rebound	rebound	NN
cord-348535-tvs1snq8	30	20	in	in	IN
cord-348535-tvs1snq8	30	21	nasopharyngeal	nasopharyngeal	JJ
cord-348535-tvs1snq8	30	22	swabs	swab	NNS
cord-348535-tvs1snq8	30	23	in	in	IN
cord-348535-tvs1snq8	30	24	rapidly	rapidly	RB
cord-348535-tvs1snq8	30	25	recovered	recover	VBN
cord-348535-tvs1snq8	30	26	and	and	CC
cord-348535-tvs1snq8	30	27	discharged	discharge	VBN
cord-348535-tvs1snq8	30	28	patients	patient	NNS
cord-348535-tvs1snq8	30	29	,	,	,
cord-348535-tvs1snq8	30	30	and	and	CC
cord-348535-tvs1snq8	30	31	thus	thus	RB
cord-348535-tvs1snq8	30	32	have	have	VBP
cord-348535-tvs1snq8	30	33	recommended	recommend	VBN
cord-348535-tvs1snq8	30	34	longer	long	JJR
cord-348535-tvs1snq8	30	35	use	use	NN
cord-348535-tvs1snq8	30	36	in	in	IN
cord-348535-tvs1snq8	30	37	the	the	DT
cord-348535-tvs1snq8	30	38	large	large	JJ
cord-348535-tvs1snq8	30	39	randomised	randomised	JJ
cord-348535-tvs1snq8	30	40	studies	study	NNS
cord-348535-tvs1snq8	30	41	in	in	IN
cord-348535-tvs1snq8	30	42	which	which	WDT
cord-348535-tvs1snq8	30	43	it	-PRON-	PRP
cord-348535-tvs1snq8	30	44	is	be	VBZ
cord-348535-tvs1snq8	30	45	included	include	VBN
cord-348535-tvs1snq8	30	46	,	,	,
cord-348535-tvs1snq8	30	47	and	and	CC
cord-348535-tvs1snq8	30	48	we	-PRON-	PRP
cord-348535-tvs1snq8	30	49	suggest	suggest	VBP
cord-348535-tvs1snq8	30	50	again	again	RB
cord-348535-tvs1snq8	30	51	that	that	IN
cord-348535-tvs1snq8	30	52	comparisons	comparison	NNS
cord-348535-tvs1snq8	30	53	between	between	IN
cord-348535-tvs1snq8	30	54	different	different	JJ
cord-348535-tvs1snq8	30	55	therapies	therapy	NNS
cord-348535-tvs1snq8	30	56	or	or	CC
cord-348535-tvs1snq8	30	57	placebo	placebo	NN
cord-348535-tvs1snq8	30	58	are	be	VBP
cord-348535-tvs1snq8	30	59	likely	likely	JJ
cord-348535-tvs1snq8	30	60	to	to	TO
cord-348535-tvs1snq8	30	61	yield	yield	VB
cord-348535-tvs1snq8	30	62	more	more	RBR
cord-348535-tvs1snq8	30	63	informative	informative	JJ
cord-348535-tvs1snq8	30	64	results	result	NNS
cord-348535-tvs1snq8	30	65	than	than	IN
cord-348535-tvs1snq8	30	66	randomised	randomised	JJ
cord-348535-tvs1snq8	30	67	studies	study	NNS
cord-348535-tvs1snq8	30	68	comparing	compare	VBG
cord-348535-tvs1snq8	30	69	10	10	CD
cord-348535-tvs1snq8	30	70	days	day	NNS
cord-348535-tvs1snq8	30	71	of	of	IN
cord-348535-tvs1snq8	30	72	intravenous	intravenous	JJ
cord-348535-tvs1snq8	30	73	remdesevir	remdesevir	NNS
cord-348535-tvs1snq8	30	74	with	with	IN
cord-348535-tvs1snq8	30	75	5	5	CD
cord-348535-tvs1snq8	30	76	days	day	NNS
cord-348535-tvs1snq8	30	77	(	(	-LRB-
cord-348535-tvs1snq8	30	78	https://benevolent.ai/news/potential-treatment-for-covid-19-identified-by-benevolentai-usingartificial-intelligence-enters-clinical-testing	https://benevolent.ai/news/potential-treatment-for-covid-19-identified-by-benevolentai-usingartificial-intelligence-enters-clinical-testing	NNP
cord-348535-tvs1snq8	30	79	And	and	CC
cord-348535-tvs1snq8	30	80	https://investor.lilly.com/news-releases/news-release-details/lilly-begins-clinical-testingtherapies-covid-19	https://investor.lilly.com/news-releases/news-release-details/lilly-begins-clinical-testingtherapies-covid-19	NNP
cord-348535-tvs1snq8	30	81	)	)	-RRB-
cord-348535-tvs1snq8	30	82	.	.	.
cord-348535-tvs1snq8	31	1	With	with	IN
cord-348535-tvs1snq8	31	2	this	this	DT
cord-348535-tvs1snq8	31	3	in	in	IN
cord-348535-tvs1snq8	31	4	mind	mind	NN
cord-348535-tvs1snq8	31	5	,	,	,
cord-348535-tvs1snq8	31	6	we	-PRON-	PRP
cord-348535-tvs1snq8	31	7	thoroughly	thoroughly	RB
cord-348535-tvs1snq8	31	8	congratulate	congratulate	VBP
cord-348535-tvs1snq8	31	9	the	the	DT
cord-348535-tvs1snq8	31	10	authors	author	NNS
cord-348535-tvs1snq8	31	11	from	from	IN
cord-348535-tvs1snq8	31	12	Guangzhou	Guangzhou	NNP
cord-348535-tvs1snq8	31	13	,	,	,
cord-348535-tvs1snq8	31	14	China	China	NNP
cord-348535-tvs1snq8	31	15	,	,	,
cord-348535-tvs1snq8	31	16	who	who	WP
cord-348535-tvs1snq8	31	17	successfully	successfully	RB
cord-348535-tvs1snq8	31	18	randomised	randomise	VBD
cord-348535-tvs1snq8	31	19	86	86	CD
cord-348535-tvs1snq8	31	20	individuals	individual	NNS
cord-348535-tvs1snq8	31	21	with	with	IN
cord-348535-tvs1snq8	31	22	mild	mild	NN
cord-348535-tvs1snq8	31	23	-	-	HYPH
cord-348535-tvs1snq8	31	24	to	to	IN
cord-348535-tvs1snq8	31	25	-	-	HYPH
cord-348535-tvs1snq8	31	26	moderate	moderate	JJ
cord-348535-tvs1snq8	31	27	COVID-19	COVID-19	NNP
cord-348535-tvs1snq8	31	28	in	in	IN
cord-348535-tvs1snq8	31	29	a	a	DT
cord-348535-tvs1snq8	31	30	2:2:1	2:2:1	CD
cord-348535-tvs1snq8	31	31	design	design	NN
cord-348535-tvs1snq8	31	32	,	,	,
cord-348535-tvs1snq8	31	33	to	to	IN
cord-348535-tvs1snq8	32	1	either	either	CC
cord-348535-tvs1snq8	32	2	lopinavir	lopinavir	NNP
cord-348535-tvs1snq8	32	3	/	/	SYM
cord-348535-tvs1snq8	32	4	ritonavir	ritonavir	NNS
cord-348535-tvs1snq8	32	5	,	,	,
cord-348535-tvs1snq8	32	6	arbidol	arbidol	NNP
cord-348535-tvs1snq8	32	7	(	(	-LRB-
cord-348535-tvs1snq8	32	8	a	a	DT
cord-348535-tvs1snq8	32	9	broad	broad	JJ
cord-348535-tvs1snq8	32	10	spectrum	spectrum	JJ
cord-348535-tvs1snq8	32	11	viral	viral	JJ
cord-348535-tvs1snq8	32	12	infusion	infusion	NN
cord-348535-tvs1snq8	32	13	inhibitor	inhibitor	NN
cord-348535-tvs1snq8	32	14	12	12	CD
cord-348535-tvs1snq8	32	15	)	)	-RRB-
cord-348535-tvs1snq8	32	16	or	or	CC
cord-348535-tvs1snq8	32	17	placebo	placebo	NN
cord-348535-tvs1snq8	32	18	(	(	-LRB-
cord-348535-tvs1snq8	32	19	NCT04252885	NCT04252885	NNP
cord-348535-tvs1snq8	32	20	)	)	-RRB-
cord-348535-tvs1snq8	32	21	.	.	.
cord-348535-tvs1snq8	33	1	Because	because	IN
cord-348535-tvs1snq8	33	2	they	-PRON-	PRP
cord-348535-tvs1snq8	33	3	included	include	VBD
cord-348535-tvs1snq8	33	4	only	only	RB
cord-348535-tvs1snq8	33	5	mild	mild	JJ
cord-348535-tvs1snq8	33	6	-	-	HYPH
cord-348535-tvs1snq8	33	7	to	to	IN
cord-348535-tvs1snq8	33	8	-	-	HYPH
cord-348535-tvs1snq8	33	9	moderate	moderate	JJ
cord-348535-tvs1snq8	33	10	patients	patient	NNS
cord-348535-tvs1snq8	33	11	,	,	,
cord-348535-tvs1snq8	33	12	the	the	DT
cord-348535-tvs1snq8	33	13	pre	pre	JJ
cord-348535-tvs1snq8	33	14	-	-	JJ
cord-348535-tvs1snq8	33	15	defined	define	VBN
cord-348535-tvs1snq8	33	16	primary	primary	JJ
cord-348535-tvs1snq8	33	17	endpoint	endpoint	NN
cord-348535-tvs1snq8	33	18	was	be	VBD
cord-348535-tvs1snq8	33	19	the	the	DT
cord-348535-tvs1snq8	33	20	conversion	conversion	NN
cord-348535-tvs1snq8	33	21	at	at	IN
cord-348535-tvs1snq8	33	22	day	day	NN
cord-348535-tvs1snq8	33	23	21	21	CD
cord-348535-tvs1snq8	33	24	of	of	IN
cord-348535-tvs1snq8	33	25	positive	positive	JJ
cord-348535-tvs1snq8	33	26	-	-	HYPH
cord-348535-tvs1snq8	33	27	to	to	IN
cord-348535-tvs1snq8	33	28	-	-	HYPH
cord-348535-tvs1snq8	33	29	negative	negative	JJ
cord-348535-tvs1snq8	33	30	PCR	PCR	NNP
cord-348535-tvs1snq8	33	31	tests	test	NNS
cord-348535-tvs1snq8	33	32	for	for	IN
cord-348535-tvs1snq8	33	33	SARS	SARS	NNP
cord-348535-tvs1snq8	33	34	-	-	HYPH
cord-348535-tvs1snq8	33	35	CoV-2	CoV-2	NNP
cord-348535-tvs1snq8	33	36	from	from	IN
cord-348535-tvs1snq8	33	37	nasopharyngeal	nasopharyngeal	JJ
cord-348535-tvs1snq8	33	38	swabs	swab	NNS
cord-348535-tvs1snq8	33	39	.	.	.
cord-348535-tvs1snq8	34	1	The	the	DT
cord-348535-tvs1snq8	34	2	real	real	JJ
cord-348535-tvs1snq8	34	3	time	time	NN
cord-348535-tvs1snq8	34	4	reverse	reverse	NN
cord-348535-tvs1snq8	34	5	-	-	HYPH
cord-348535-tvs1snq8	34	6	transcriptase	transcriptase	NN
cord-348535-tvs1snq8	34	7	PCR	PCR	NNP
cord-348535-tvs1snq8	34	8	(	(	-LRB-
cord-348535-tvs1snq8	34	9	RT	RT	NNP
cord-348535-tvs1snq8	34	10	-	-	HYPH
cord-348535-tvs1snq8	34	11	PCR	PCR	NNP
cord-348535-tvs1snq8	34	12	)	)	-RRB-
cord-348535-tvs1snq8	34	13	method	method	NN
cord-348535-tvs1snq8	34	14	used	use	VBN
cord-348535-tvs1snq8	34	15	was	be	VBD
cord-348535-tvs1snq8	34	16	indeed	indeed	RB
cord-348535-tvs1snq8	34	17	appropriate	appropriate	JJ
cord-348535-tvs1snq8	34	18	as	as	IN
cord-348535-tvs1snq8	34	19	it	-PRON-	PRP
cord-348535-tvs1snq8	34	20	was	be	VBD
cord-348535-tvs1snq8	34	21	performed	perform	VBN
cord-348535-tvs1snq8	34	22	simultaneously	simultaneously	RB
cord-348535-tvs1snq8	34	23	on	on	IN
cord-348535-tvs1snq8	34	24	two	two	CD
cord-348535-tvs1snq8	34	25	target	target	NN
cord-348535-tvs1snq8	34	26	genes	gene	NNS
cord-348535-tvs1snq8	34	27	,	,	,
cord-348535-tvs1snq8	34	28	ORF1ab	ORF1ab	NNP
cord-348535-tvs1snq8	34	29	and	and	CC
cord-348535-tvs1snq8	34	30	N	n	CD
cord-348535-tvs1snq8	34	31	genes	gene	NNS
cord-348535-tvs1snq8	34	32	,	,	,
cord-348535-tvs1snq8	34	33	and	and	CC
cord-348535-tvs1snq8	34	34	positive	positive	JJ
cord-348535-tvs1snq8	34	35	and	and	CC
cord-348535-tvs1snq8	34	36	negative	negative	JJ
cord-348535-tvs1snq8	34	37	controls	control	NNS
cord-348535-tvs1snq8	34	38	were	be	VBD
cord-348535-tvs1snq8	34	39	used	use	VBN
cord-348535-tvs1snq8	34	40	at	at	IN
cord-348535-tvs1snq8	34	41	each	each	DT
cord-348535-tvs1snq8	34	42	batch	batch	NN
cord-348535-tvs1snq8	34	43	.	.	.
cord-348535-tvs1snq8	35	1	Negative	negative	JJ
cord-348535-tvs1snq8	35	2	conversion	conversion	NN
cord-348535-tvs1snq8	35	3	required	require	VBD
cord-348535-tvs1snq8	35	4	2	2	CD
cord-348535-tvs1snq8	35	5	separate	separate	JJ
cord-348535-tvs1snq8	35	6	real	real	JJ
cord-348535-tvs1snq8	35	7	time	time	NN
cord-348535-tvs1snq8	35	8	RT	rt	NN
cord-348535-tvs1snq8	35	9	-	-	HYPH
cord-348535-tvs1snq8	35	10	PCR	PCR	NNP
cord-348535-tvs1snq8	35	11	tests	test	NNS
cord-348535-tvs1snq8	35	12	separated	separate	VBN
cord-348535-tvs1snq8	35	13	by	by	IN
cord-348535-tvs1snq8	35	14	24	24	CD
cord-348535-tvs1snq8	35	15	hours	hour	NNS
cord-348535-tvs1snq8	35	16	,	,	,
cord-348535-tvs1snq8	35	17	and	and	CC
cord-348535-tvs1snq8	35	18	the	the	DT
cord-348535-tvs1snq8	35	19	entry	entry	NN
cord-348535-tvs1snq8	35	20	criteria	criterion	NNS
cord-348535-tvs1snq8	35	21	for	for	IN
cord-348535-tvs1snq8	35	22	the	the	DT
cord-348535-tvs1snq8	35	23	definition	definition	NN
cord-348535-tvs1snq8	35	24	of	of	IN
cord-348535-tvs1snq8	35	25	mild	mild	JJ
cord-348535-tvs1snq8	35	26	-	-	HYPH
cord-348535-tvs1snq8	35	27	to	to	IN
cord-348535-tvs1snq8	35	28	-	-	HYPH
cord-348535-tvs1snq8	35	29	moderate	moderate	JJ
cord-348535-tvs1snq8	35	30	including	include	VBG
cord-348535-tvs1snq8	35	31	the	the	DT
cord-348535-tvs1snq8	35	32	absence	absence	NN
cord-348535-tvs1snq8	35	33	of	of	IN
cord-348535-tvs1snq8	35	34	pneumonia	pneumonia	NN
cord-348535-tvs1snq8	35	35	are	be	VBP
cord-348535-tvs1snq8	35	36	entirely	entirely	RB
cord-348535-tvs1snq8	35	37	appropriate	appropriate	JJ
cord-348535-tvs1snq8	35	38	.	.	.
cord-348535-tvs1snq8	36	1	Baseline	baseline	JJ
cord-348535-tvs1snq8	36	2	criteria	criterion	NNS
cord-348535-tvs1snq8	36	3	between	between	IN
cord-348535-tvs1snq8	36	4	the	the	DT
cord-348535-tvs1snq8	36	5	3	3	CD
cord-348535-tvs1snq8	36	6	groups	group	NNS
cord-348535-tvs1snq8	36	7	were	be	VBD
cord-348535-tvs1snq8	36	8	well	well	RB
cord-348535-tvs1snq8	36	9	-	-	HYPH
cord-348535-tvs1snq8	36	10	matched	match	VBN
cord-348535-tvs1snq8	36	11	(	(	-LRB-
cord-348535-tvs1snq8	36	12	a	a	DT
cord-348535-tvs1snq8	36	13	criticism	criticism	NN
cord-348535-tvs1snq8	36	14	of	of	IN
cord-348535-tvs1snq8	36	15	one	one	CD
cord-348535-tvs1snq8	36	16	of	of	IN
cord-348535-tvs1snq8	36	17	the	the	DT
cord-348535-tvs1snq8	36	18	hydroxychloroquine	hydroxychloroquine	NN
cord-348535-tvs1snq8	36	19	randomised	randomised	JJ
cord-348535-tvs1snq8	36	20	studies	study	NNS
cord-348535-tvs1snq8	36	21	is	be	VBZ
cord-348535-tvs1snq8	36	22	this	this	DT
cord-348535-tvs1snq8	36	23	was	be	VBD
cord-348535-tvs1snq8	36	24	not	not	RB
cord-348535-tvs1snq8	36	25	the	the	DT
cord-348535-tvs1snq8	36	26	case	case	NN
cord-348535-tvs1snq8	36	27	13	13	CD
cord-348535-tvs1snq8	36	28	)	)	-RRB-
cord-348535-tvs1snq8	36	29	and	and	CC
cord-348535-tvs1snq8	36	30	follow	follow	VB
cord-348535-tvs1snq8	36	31	up	up	RP
cord-348535-tvs1snq8	36	32	was	be	VBD
cord-348535-tvs1snq8	36	33	appropriate	appropriate	JJ
cord-348535-tvs1snq8	36	34	.	.	.
cord-348535-tvs1snq8	37	1	Their	-PRON-	PRP$
cord-348535-tvs1snq8	37	2	data	datum	NNS
cord-348535-tvs1snq8	37	3	helpfully	helpfully	RB
cord-348535-tvs1snq8	37	4	shows	show	VBZ
cord-348535-tvs1snq8	37	5	there	there	EX
cord-348535-tvs1snq8	37	6	was	be	VBD
cord-348535-tvs1snq8	37	7	no	no	DT
cord-348535-tvs1snq8	37	8	difference	difference	NN
cord-348535-tvs1snq8	37	9	between	between	IN
cord-348535-tvs1snq8	37	10	any	any	DT
cord-348535-tvs1snq8	37	11	of	of	IN
cord-348535-tvs1snq8	37	12	the	the	DT
cord-348535-tvs1snq8	37	13	groups	group	NNS
cord-348535-tvs1snq8	37	14	in	in	IN
cord-348535-tvs1snq8	37	15	the	the	DT
cord-348535-tvs1snq8	37	16	primary	primary	JJ
cord-348535-tvs1snq8	37	17	endpoint	endpoint	NN
cord-348535-tvs1snq8	37	18	.	.	.
cord-348535-tvs1snq8	38	1	In	in	IN
cord-348535-tvs1snq8	38	2	the	the	DT
cord-348535-tvs1snq8	38	3	continuing	continue	VBG
cord-348535-tvs1snq8	38	4	search	search	NN
cord-348535-tvs1snq8	38	5	for	for	IN
cord-348535-tvs1snq8	38	6	safe	safe	JJ
cord-348535-tvs1snq8	38	7	and	and	CC
cord-348535-tvs1snq8	38	8	effective	effective	JJ
cord-348535-tvs1snq8	38	9	new	new	JJ
cord-348535-tvs1snq8	38	10	therapies	therapy	NNS
cord-348535-tvs1snq8	38	11	to	to	TO
cord-348535-tvs1snq8	38	12	treat	treat	VB
cord-348535-tvs1snq8	38	13	patients	patient	NNS
cord-348535-tvs1snq8	38	14	with	with	IN
cord-348535-tvs1snq8	38	15	COVID-19	COVID-19	NNP
cord-348535-tvs1snq8	38	16	,	,	,
cord-348535-tvs1snq8	38	17	we	-PRON-	PRP
cord-348535-tvs1snq8	38	18	require	require	VBP
cord-348535-tvs1snq8	38	19	well	well	RB
cord-348535-tvs1snq8	38	20	-	-	HYPH
cord-348535-tvs1snq8	38	21	conducted	conduct	VBN
cord-348535-tvs1snq8	38	22	ethical	ethical	JJ
cord-348535-tvs1snq8	38	23	studies	study	NNS
cord-348535-tvs1snq8	38	24	including	include	VBG
cord-348535-tvs1snq8	38	25	prospective	prospective	JJ
cord-348535-tvs1snq8	38	26	,	,	,
cord-348535-tvs1snq8	38	27	randomised	randomised	JJ
cord-348535-tvs1snq8	38	28	,	,	,
cord-348535-tvs1snq8	38	29	placebocontrolled	placebocontrolled	JJ
cord-348535-tvs1snq8	38	30	clinical	clinical	JJ
cord-348535-tvs1snq8	38	31	studies	study	NNS
cord-348535-tvs1snq8	38	32	such	such	JJ
cord-348535-tvs1snq8	38	33	as	as	IN
cord-348535-tvs1snq8	38	34	this	this	DT
cord-348535-tvs1snq8	38	35	.	.	.
cord-348535-tvs1snq8	39	1	Although	although	IN
cord-348535-tvs1snq8	39	2	many	many	JJ
cord-348535-tvs1snq8	39	3	drugs	drug	NNS
cord-348535-tvs1snq8	39	4	have	have	VBP
cord-348535-tvs1snq8	39	5	predicted	predict	VBN
cord-348535-tvs1snq8	39	6	in	in	IN
cord-348535-tvs1snq8	39	7	vitro	vitro	FW
cord-348535-tvs1snq8	39	8	activity	activity	NN
cord-348535-tvs1snq8	39	9	against	against	IN
cord-348535-tvs1snq8	39	10	the	the	DT
cord-348535-tvs1snq8	39	11	virus	virus	NN
cord-348535-tvs1snq8	39	12	,	,	,
cord-348535-tvs1snq8	39	13	the	the	DT
cord-348535-tvs1snq8	39	14	proposal	proposal	NN
cord-348535-tvs1snq8	39	15	that	that	IN
cord-348535-tvs1snq8	39	16	such	such	JJ
cord-348535-tvs1snq8	39	17	drugs	drug	NNS
cord-348535-tvs1snq8	39	18	might	may	MD
cord-348535-tvs1snq8	39	19	provide	provide	VB
cord-348535-tvs1snq8	39	20	more	more	JJR
cord-348535-tvs1snq8	39	21	benefit	benefit	NN
cord-348535-tvs1snq8	39	22	than	than	IN
cord-348535-tvs1snq8	39	23	harm	harm	NN
cord-348535-tvs1snq8	39	24	is	be	VBZ
cord-348535-tvs1snq8	39	25	not	not	RB
cord-348535-tvs1snq8	39	26	appropriate	appropriate	JJ
cord-348535-tvs1snq8	39	27	with	with	IN
cord-348535-tvs1snq8	39	28	no	no	DT
cord-348535-tvs1snq8	39	29	evidence	evidence	NN
cord-348535-tvs1snq8	39	30	base	base	NN
cord-348535-tvs1snq8	39	31	supporting	support	VBG
cord-348535-tvs1snq8	39	32	efficacy	efficacy	NN
cord-348535-tvs1snq8	39	33	in	in	IN
cord-348535-tvs1snq8	39	34	any	any	DT
cord-348535-tvs1snq8	39	35	patients	patient	NNS
cord-348535-tvs1snq8	39	36	infected	infect	VBN
cord-348535-tvs1snq8	39	37	with	with	IN
cord-348535-tvs1snq8	39	38	SARS	SARS	NNP
cord-348535-tvs1snq8	39	39	-	-	HYPH
cord-348535-tvs1snq8	39	40	CoV-2	CoV-2	NNP
cord-348535-tvs1snq8	39	41	.	.	.
cord-348535-tvs1snq8	40	1	A	a	DT
cord-348535-tvs1snq8	40	2	preprint	preprint	NN
cord-348535-tvs1snq8	40	3	reporting	report	VBG
cord-348535-tvs1snq8	40	4	results	result	NNS
cord-348535-tvs1snq8	40	5	from	from	IN
cord-348535-tvs1snq8	40	6	a	a	DT
cord-348535-tvs1snq8	40	7	randomised	randomised	JJ
cord-348535-tvs1snq8	40	8	trial	trial	NN
cord-348535-tvs1snq8	40	9	of	of	IN
cord-348535-tvs1snq8	40	10	the	the	DT
cord-348535-tvs1snq8	40	11	anti	anti	JJ
cord-348535-tvs1snq8	40	12	-	-	JJ
cord-348535-tvs1snq8	40	13	viral	viral	JJ
cord-348535-tvs1snq8	40	14	favipravir	favipravir	NNS
cord-348535-tvs1snq8	40	15	versus	versus	IN
cord-348535-tvs1snq8	40	16	arbidol	arbidol	NN
cord-348535-tvs1snq8	40	17	in	in	IN
cord-348535-tvs1snq8	40	18	240	240	CD
cord-348535-tvs1snq8	40	19	adults	adult	NNS
cord-348535-tvs1snq8	40	20	has	have	VBZ
cord-348535-tvs1snq8	40	21	shown	show	VBN
cord-348535-tvs1snq8	40	22	no	no	DT
cord-348535-tvs1snq8	40	23	difference	difference	NN
cord-348535-tvs1snq8	40	24	in	in	IN
cord-348535-tvs1snq8	40	25	clinical	clinical	JJ
cord-348535-tvs1snq8	40	26	recovery	recovery	NN
cord-348535-tvs1snq8	40	27	at	at	IN
cord-348535-tvs1snq8	40	28	7	7	CD
cord-348535-tvs1snq8	40	29	days	day	NNS
cord-348535-tvs1snq8	40	30	,	,	,
cord-348535-tvs1snq8	40	31	but	but	CC
cord-348535-tvs1snq8	40	32	cough	cough	NN
cord-348535-tvs1snq8	40	33	and	and	CC
cord-348535-tvs1snq8	40	34	pyrexia	pyrexia	NN
cord-348535-tvs1snq8	40	35	were	be	VBD
cord-348535-tvs1snq8	40	36	improved	improve	VBN
cord-348535-tvs1snq8	40	37	on	on	IN
cord-348535-tvs1snq8	40	38	favipravir	favipravir	NNS
cord-348535-tvs1snq8	40	39	.	.	.
cord-348535-tvs1snq8	41	1	14	14	CD
cord-348535-tvs1snq8	42	1	These	these	DT
cord-348535-tvs1snq8	42	2	authors	author	NNS
cord-348535-tvs1snq8	42	3	and	and	CC
cord-348535-tvs1snq8	42	4	Li	Li	NNP
cord-348535-tvs1snq8	42	5	et	et	NNP
cord-348535-tvs1snq8	42	6	al	al	NNP
cord-348535-tvs1snq8	42	7	.	.	NNP
cord-348535-tvs1snq8	42	8	should	should	MD
cord-348535-tvs1snq8	42	9	be	be	VB
cord-348535-tvs1snq8	42	10	applauded	applaud	VBN
cord-348535-tvs1snq8	42	11	for	for	IN
cord-348535-tvs1snq8	42	12	their	-PRON-	PRP$
cord-348535-tvs1snq8	42	13	efforts	effort	NNS
cord-348535-tvs1snq8	42	14	to	to	TO
cord-348535-tvs1snq8	42	15	add	add	VB
cord-348535-tvs1snq8	42	16	a	a	DT
cord-348535-tvs1snq8	42	17	useful	useful	JJ
cord-348535-tvs1snq8	42	18	randomised	randomised	JJ
cord-348535-tvs1snq8	42	19	trial	trial	NN
cord-348535-tvs1snq8	42	20	to	to	IN
cord-348535-tvs1snq8	42	21	the	the	DT
cord-348535-tvs1snq8	42	22	literature	literature	NN
cord-348535-tvs1snq8	42	23	,	,	,
cord-348535-tvs1snq8	42	24	albeit	albeit	IN
cord-348535-tvs1snq8	42	25	one	one	CD
cord-348535-tvs1snq8	42	26	that	that	WDT
cord-348535-tvs1snq8	42	27	is	be	VBZ
cord-348535-tvs1snq8	42	28	negative	negative	JJ
cord-348535-tvs1snq8	42	29	.	.	.
cord-348535-tvs1snq8	43	1	It	-PRON-	PRP
cord-348535-tvs1snq8	43	2	is	be	VBZ
cord-348535-tvs1snq8	43	3	critical	critical	JJ
cord-348535-tvs1snq8	43	4	to	to	TO
cord-348535-tvs1snq8	43	5	publish	publish	VB
cord-348535-tvs1snq8	43	6	such	such	JJ
cord-348535-tvs1snq8	43	7	studies	study	NNS
cord-348535-tvs1snq8	43	8	.	.	.
cord-348535-tvs1snq8	44	1	International	International	NNP
cord-348535-tvs1snq8	44	2	multicentre	multicentre	NNP
cord-348535-tvs1snq8	44	3	trials	trial	NNS
cord-348535-tvs1snq8	44	4	,	,	,
cord-348535-tvs1snq8	44	5	such	such	JJ
cord-348535-tvs1snq8	44	6	as	as	IN
cord-348535-tvs1snq8	44	7	Discovery	Discovery	NNP
cord-348535-tvs1snq8	44	8	(	(	-LRB-
cord-348535-tvs1snq8	44	9	NCT04315948	NCT04315948	NNP
cord-348535-tvs1snq8	44	10	)	)	-RRB-
cord-348535-tvs1snq8	44	11	and	and	CC
cord-348535-tvs1snq8	44	12	Solidarity	Solidarity	NNP
cord-348535-tvs1snq8	44	13	(	(	-LRB-
cord-348535-tvs1snq8	44	14	EudraCT	EudraCT	NNP
cord-348535-tvs1snq8	44	15	Number	Number	NNP
cord-348535-tvs1snq8	44	16	2020	2020	CD
cord-348535-tvs1snq8	44	17	-	-	HYPH
cord-348535-tvs1snq8	44	18	000982	000982	CD
cord-348535-tvs1snq8	44	19	-	-	SYM
cord-348535-tvs1snq8	44	20	18	18	CD
cord-348535-tvs1snq8	44	21	)	)	-RRB-
cord-348535-tvs1snq8	44	22	,	,	,
cord-348535-tvs1snq8	44	23	will	will	MD
cord-348535-tvs1snq8	44	24	randomise	randomise	VB
cord-348535-tvs1snq8	44	25	patients	patient	NNS
cord-348535-tvs1snq8	44	26	with	with	IN
cord-348535-tvs1snq8	44	27	COVID-19	COVID-19	NNP
cord-348535-tvs1snq8	44	28	to	to	TO
cord-348535-tvs1snq8	44	29	receive	receive	VB
cord-348535-tvs1snq8	44	30	different	different	JJ
cord-348535-tvs1snq8	44	31	drugs	drug	NNS
cord-348535-tvs1snq8	44	32	in	in	IN
cord-348535-tvs1snq8	44	33	adaptive	adaptive	JJ
cord-348535-tvs1snq8	44	34	study	study	NN
cord-348535-tvs1snq8	44	35	designs	design	NNS
cord-348535-tvs1snq8	44	36	.	.	.
cord-348535-tvs1snq8	45	1	Such	such	JJ
cord-348535-tvs1snq8	45	2	initiatives	initiative	NNS
cord-348535-tvs1snq8	45	3	will	will	MD
cord-348535-tvs1snq8	45	4	provide	provide	VB
cord-348535-tvs1snq8	45	5	the	the	DT
cord-348535-tvs1snq8	45	6	best	good	JJS
cord-348535-tvs1snq8	45	7	and	and	CC
cord-348535-tvs1snq8	45	8	most	most	RBS
cord-348535-tvs1snq8	45	9	relevant	relevant	JJ
cord-348535-tvs1snq8	45	10	data	datum	NNS
cord-348535-tvs1snq8	45	11	to	to	TO
cord-348535-tvs1snq8	45	12	guide	guide	VB
cord-348535-tvs1snq8	45	13	management	management	NN
cord-348535-tvs1snq8	45	14	of	of	IN
cord-348535-tvs1snq8	45	15	patients	patient	NNS
cord-348535-tvs1snq8	45	16	with	with	IN
cord-348535-tvs1snq8	45	17	COVID-19	COVID-19	NNP
cord-348535-tvs1snq8	45	18	.	.	.
cord-348535-tvs1snq8	46	1	Whether	whether	IN
cord-348535-tvs1snq8	46	2	antiviral	antiviral	JJ
cord-348535-tvs1snq8	46	3	,	,	,
cord-348535-tvs1snq8	46	4	immunomodulatory	immunomodulatory	JJ
cord-348535-tvs1snq8	46	5	or	or	CC
cord-348535-tvs1snq8	46	6	antimalarial	antimalarial	JJ
cord-348535-tvs1snq8	46	7	drugs	drug	NNS
cord-348535-tvs1snq8	46	8	could	could	MD
cord-348535-tvs1snq8	46	9	be	be	VB
cord-348535-tvs1snq8	46	10	effective	effective	JJ
cord-348535-tvs1snq8	46	11	in	in	IN
cord-348535-tvs1snq8	46	12	changing	change	VBG
cord-348535-tvs1snq8	46	13	the	the	DT
cord-348535-tvs1snq8	46	14	disease	disease	NN
cord-348535-tvs1snq8	46	15	course	course	NN
cord-348535-tvs1snq8	46	16	in	in	IN
cord-348535-tvs1snq8	46	17	patients	patient	NNS
cord-348535-tvs1snq8	46	18	with	with	IN
cord-348535-tvs1snq8	46	19	either	either	CC
cord-348535-tvs1snq8	46	20	mild	mild	JJ
cord-348535-tvs1snq8	46	21	or	or	CC
cord-348535-tvs1snq8	46	22	severe	severe	JJ
cord-348535-tvs1snq8	46	23	COVID-19	covid-19	NN
cord-348535-tvs1snq8	46	24	remains	remain	VBZ
cord-348535-tvs1snq8	46	25	unknown	unknown	JJ
cord-348535-tvs1snq8	46	26	.	.	.
cord-348535-tvs1snq8	47	1	When	when	WRB
cord-348535-tvs1snq8	47	2	patients	patient	NNS
cord-348535-tvs1snq8	47	3	take	take	VBP
cord-348535-tvs1snq8	47	4	these	these	DT
cord-348535-tvs1snq8	47	5	off	off	IN
cord-348535-tvs1snq8	47	6	-	-	HYPH
cord-348535-tvs1snq8	47	7	label	label	NN
cord-348535-tvs1snq8	47	8	and	and	CC
cord-348535-tvs1snq8	47	9	recover	recover	VB
cord-348535-tvs1snq8	47	10	it	-PRON-	PRP
cord-348535-tvs1snq8	47	11	is	be	VBZ
cord-348535-tvs1snq8	47	12	not	not	RB
cord-348535-tvs1snq8	47	13	known	know	VBN
cord-348535-tvs1snq8	47	14	whether	whether	IN
cord-348535-tvs1snq8	47	15	the	the	DT
cord-348535-tvs1snq8	47	16	drug	drug	NN
cord-348535-tvs1snq8	47	17	was	be	VBD
cord-348535-tvs1snq8	47	18	helpful	helpful	JJ
cord-348535-tvs1snq8	47	19	in	in	IN
cord-348535-tvs1snq8	47	20	the	the	DT
cord-348535-tvs1snq8	47	21	disease	disease	NN
cord-348535-tvs1snq8	47	22	course	course	NN
cord-348535-tvs1snq8	47	23	without	without	IN
cord-348535-tvs1snq8	47	24	randomisation	randomisation	NN
cord-348535-tvs1snq8	47	25	.	.	.
cord-348535-tvs1snq8	48	1	Similarly	similarly	RB
cord-348535-tvs1snq8	48	2	,	,	,
cord-348535-tvs1snq8	48	3	when	when	WRB
cord-348535-tvs1snq8	48	4	patients	patient	NNS
cord-348535-tvs1snq8	48	5	deteriorate	deteriorate	VBP
cord-348535-tvs1snq8	48	6	,	,	,
cord-348535-tvs1snq8	48	7	we	-PRON-	PRP
cord-348535-tvs1snq8	48	8	do	do	VBP
cord-348535-tvs1snq8	48	9	not	not	RB
cord-348535-tvs1snq8	48	10	know	know	VB
cord-348535-tvs1snq8	48	11	if	if	IN
cord-348535-tvs1snq8	48	12	they	-PRON-	PRP
cord-348535-tvs1snq8	48	13	should	should	MD
cord-348535-tvs1snq8	48	14	be	be	VB
cord-348535-tvs1snq8	48	15	continued	continue	VBN
cord-348535-tvs1snq8	48	16	or	or	CC
cord-348535-tvs1snq8	48	17	considered	consider	VBN
cord-348535-tvs1snq8	48	18	clinically	clinically	RB
cord-348535-tvs1snq8	48	19	ineffective	ineffective	JJ
cord-348535-tvs1snq8	48	20	and	and	CC
cord-348535-tvs1snq8	48	21	stopped	stop	VBD
cord-348535-tvs1snq8	48	22	.	.	.
cord-348535-tvs1snq8	49	1	Assessing	assess	VBG
cord-348535-tvs1snq8	49	2	viral	viral	JJ
cord-348535-tvs1snq8	49	3	loads	load	NNS
cord-348535-tvs1snq8	49	4	by	by	IN
cord-348535-tvs1snq8	49	5	PCR	PCR	NNP
cord-348535-tvs1snq8	49	6	on	on	IN
cord-348535-tvs1snq8	49	7	nasopharyngeal	nasopharyngeal	JJ
cord-348535-tvs1snq8	49	8	swabs	swab	NNS
cord-348535-tvs1snq8	49	9	as	as	IN
cord-348535-tvs1snq8	49	10	performed	perform	VBN
cord-348535-tvs1snq8	49	11	in	in	IN
cord-348535-tvs1snq8	49	12	the	the	DT
cord-348535-tvs1snq8	49	13	trial	trial	NN
cord-348535-tvs1snq8	49	14	here	here	RB
cord-348535-tvs1snq8	49	15	,	,	,
cord-348535-tvs1snq8	49	16	will	will	MD
cord-348535-tvs1snq8	49	17	help	help	VB
cord-348535-tvs1snq8	49	18	clarify	clarify	VB
cord-348535-tvs1snq8	49	19	the	the	DT
cord-348535-tvs1snq8	49	20	roles	role	NNS
cord-348535-tvs1snq8	49	21	of	of	IN
cord-348535-tvs1snq8	49	22	these	these	DT
cord-348535-tvs1snq8	49	23	medicines	medicine	NNS
cord-348535-tvs1snq8	49	24	going	go	VBG
cord-348535-tvs1snq8	49	25	forwards	forwards	RB
cord-348535-tvs1snq8	49	26	.	.	.
cord-348535-tvs1snq8	50	1	COVID-19	covid-19	LS
cord-348535-tvs1snq8	50	2	:	:	:
cord-348535-tvs1snq8	50	3	extending	extend	VBG
cord-348535-tvs1snq8	50	4	or	or	CC
cord-348535-tvs1snq8	50	5	relaxing	relax	VBG
cord-348535-tvs1snq8	50	6	distancing	distance	VBG
cord-348535-tvs1snq8	50	7	control	control	NN
cord-348535-tvs1snq8	50	8	measures	measure	NNS
cord-348535-tvs1snq8	50	9	Impact	Impact	NNP
cord-348535-tvs1snq8	50	10	assessment	assessment	NN
cord-348535-tvs1snq8	50	11	of	of	IN
cord-348535-tvs1snq8	50	12	non	non	JJ
cord-348535-tvs1snq8	50	13	-	-	JJ
cord-348535-tvs1snq8	50	14	pharmaceutical	pharmaceutical	JJ
cord-348535-tvs1snq8	50	15	interventions	intervention	NNS
cord-348535-tvs1snq8	50	16	against	against	IN
cord-348535-tvs1snq8	50	17	coronavirus	coronavirus	NN
cord-348535-tvs1snq8	50	18	disease	disease	NN
cord-348535-tvs1snq8	50	19	2019	2019	CD
cord-348535-tvs1snq8	50	20	and	and	CC
cord-348535-tvs1snq8	50	21	influenza	influenza	NN
cord-348535-tvs1snq8	50	22	in	in	IN
cord-348535-tvs1snq8	50	23	Hong	Hong	NNP
cord-348535-tvs1snq8	50	24	Kong	Kong	NNP
cord-348535-tvs1snq8	51	1	:	:	:
cord-348535-tvs1snq8	51	2	an	an	DT
cord-348535-tvs1snq8	51	3	observational	observational	JJ
cord-348535-tvs1snq8	51	4	study	study	NN
cord-348535-tvs1snq8	52	1	The	the	DT
cord-348535-tvs1snq8	52	2	effect	effect	NN
cord-348535-tvs1snq8	52	3	of	of	IN
cord-348535-tvs1snq8	52	4	control	control	NN
cord-348535-tvs1snq8	52	5	strategies	strategy	NNS
cord-348535-tvs1snq8	52	6	to	to	TO
cord-348535-tvs1snq8	52	7	reduce	reduce	VB
cord-348535-tvs1snq8	52	8	social	social	JJ
cord-348535-tvs1snq8	52	9	mixing	mixing	NN
cord-348535-tvs1snq8	52	10	on	on	IN
cord-348535-tvs1snq8	52	11	outcomes	outcome	NNS
cord-348535-tvs1snq8	52	12	of	of	IN
cord-348535-tvs1snq8	52	13	the	the	DT
cord-348535-tvs1snq8	52	14	COVID-19	covid-19	JJ
cord-348535-tvs1snq8	52	15	epidemic	epidemic	NN
cord-348535-tvs1snq8	52	16	in	in	IN
cord-348535-tvs1snq8	52	17	Wuhan	Wuhan	NNP
cord-348535-tvs1snq8	52	18	,	,	,
cord-348535-tvs1snq8	52	19	China	China	NNP
cord-348535-tvs1snq8	52	20	:	:	:
cord-348535-tvs1snq8	52	21	a	a	DT
cord-348535-tvs1snq8	52	22	modelling	modelling	NN
cord-348535-tvs1snq8	52	23	study	study	NN
cord-348535-tvs1snq8	52	24	Baricitinib	Baricitinib	NNP
cord-348535-tvs1snq8	52	25	as	as	IN
cord-348535-tvs1snq8	52	26	potential	potential	JJ
cord-348535-tvs1snq8	52	27	treatment	treatment	NN
cord-348535-tvs1snq8	52	28	for	for	IN
cord-348535-tvs1snq8	52	29	2019-nCoV	2019-ncov	CD
cord-348535-tvs1snq8	52	30	acute	acute	JJ
cord-348535-tvs1snq8	52	31	respiratory	respiratory	JJ
cord-348535-tvs1snq8	52	32	disease	disease	NN
cord-348535-tvs1snq8	52	33	COVID-19	covid-19	NN
cord-348535-tvs1snq8	52	34	:	:	:
cord-348535-tvs1snq8	52	35	combining	combine	VBG
cord-348535-tvs1snq8	52	36	antiviral	antiviral	JJ
cord-348535-tvs1snq8	52	37	and	and	CC
cord-348535-tvs1snq8	52	38	anti	anti	JJ
cord-348535-tvs1snq8	52	39	-	-	JJ
cord-348535-tvs1snq8	52	40	inflammatory	inflammatory	JJ
cord-348535-tvs1snq8	52	41	treatments	treatment	NNS
cord-348535-tvs1snq8	53	1	A	a	DT
cord-348535-tvs1snq8	53	2	Trial	Trial	NNP
cord-348535-tvs1snq8	53	3	of	of	IN
cord-348535-tvs1snq8	53	4	Lopinavir	Lopinavir	NNP
cord-348535-tvs1snq8	53	5	-	-	HYPH
cord-348535-tvs1snq8	53	6	Ritonavir	Ritonavir	NNP
cord-348535-tvs1snq8	53	7	in	in	IN
cord-348535-tvs1snq8	53	8	Adults	Adults	NNPS
cord-348535-tvs1snq8	53	9	Hospitalized	hospitalize	VBN
cord-348535-tvs1snq8	53	10	with	with	IN
cord-348535-tvs1snq8	53	11	Severe	severe	JJ
cord-348535-tvs1snq8	53	12	Covid-19	covid-19	NN
cord-348535-tvs1snq8	53	13	Compassionate	compassionate	JJ
cord-348535-tvs1snq8	53	14	Use	Use	NNP
cord-348535-tvs1snq8	53	15	of	of	IN
cord-348535-tvs1snq8	53	16	Remdesivir	Remdesivir	NNP
cord-348535-tvs1snq8	53	17	for	for	IN
cord-348535-tvs1snq8	53	18	Patients	patient	NNS
cord-348535-tvs1snq8	53	19	with	with	IN
cord-348535-tvs1snq8	53	20	Severe	severe	JJ
cord-348535-tvs1snq8	53	21	Covid-19	Covid-19	NNP
cord-348535-tvs1snq8	53	22	Clinical	clinical	JJ
cord-348535-tvs1snq8	53	23	and	and	CC
cord-348535-tvs1snq8	53	24	virological	virological	JJ
cord-348535-tvs1snq8	53	25	data	datum	NNS
cord-348535-tvs1snq8	53	26	of	of	IN
cord-348535-tvs1snq8	53	27	the	the	DT
cord-348535-tvs1snq8	53	28	first	first	JJ
cord-348535-tvs1snq8	53	29	cases	case	NNS
cord-348535-tvs1snq8	53	30	of	of	IN
cord-348535-tvs1snq8	53	31	COVID-19	covid-19	CD
cord-348535-tvs1snq8	53	32	in	in	IN
cord-348535-tvs1snq8	53	33	Europe	Europe	NNP
cord-348535-tvs1snq8	53	34	:	:	:
cord-348535-tvs1snq8	54	1	a	a	DT
cord-348535-tvs1snq8	54	2	case	case	NN
cord-348535-tvs1snq8	54	3	series	series	NN
cord-348535-tvs1snq8	54	4	Chloroquine	Chloroquine	NNP
cord-348535-tvs1snq8	54	5	for	for	IN
cord-348535-tvs1snq8	54	6	COVID-19	COVID-19	NNP
cord-348535-tvs1snq8	54	7	Infection	Infection	NNP
cord-348535-tvs1snq8	54	8	Mechanism	Mechanism	NNP
cord-348535-tvs1snq8	54	9	of	of	IN
cord-348535-tvs1snq8	54	10	baricitinib	baricitinib	NNP
cord-348535-tvs1snq8	54	11	supports	support	VBZ
cord-348535-tvs1snq8	54	12	artificial	artificial	JJ
cord-348535-tvs1snq8	54	13	intelligence	intelligence	NN
cord-348535-tvs1snq8	54	14	-	-	HYPH
cord-348535-tvs1snq8	54	15	predicted	predict	VBN
cord-348535-tvs1snq8	54	16	testing	testing	NN
cord-348535-tvs1snq8	54	17	in	in	IN
cord-348535-tvs1snq8	54	18	COVID-19	COVID-19	NNP
cord-348535-tvs1snq8	54	19	patients	patient	NNS
cord-348535-tvs1snq8	54	20	Arbidol	Arbidol	NNP
cord-348535-tvs1snq8	54	21	:	:	:
cord-348535-tvs1snq8	54	22	a	a	DT
cord-348535-tvs1snq8	54	23	broad	broad	JJ
cord-348535-tvs1snq8	54	24	-	-	HYPH
cord-348535-tvs1snq8	54	25	spectrum	spectrum	NN
cord-348535-tvs1snq8	54	26	antiviral	antiviral	JJ
cord-348535-tvs1snq8	54	27	compound	compound	NN
cord-348535-tvs1snq8	54	28	that	that	WDT
cord-348535-tvs1snq8	54	29	blocks	block	VBZ
cord-348535-tvs1snq8	54	30	viral	viral	JJ
cord-348535-tvs1snq8	54	31	fusion	fusion	NN
cord-348535-tvs1snq8	54	32	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-348535-tvs1snq8	54	33	in	in	IN
cord-348535-tvs1snq8	54	34	the	the	DT
cord-348535-tvs1snq8	54	35	management	management	NN
cord-348535-tvs1snq8	54	36	of	of	IN
cord-348535-tvs1snq8	54	37	critically	critically	RB
cord-348535-tvs1snq8	54	38	ill	ill	JJ
cord-348535-tvs1snq8	54	39	patients	patient	NNS
cord-348535-tvs1snq8	54	40	with	with	IN
cord-348535-tvs1snq8	54	41	COVID-19	covid-19	VB
cord-348535-tvs1snq8	54	42	:	:	:
cord-348535-tvs1snq8	54	43	the	the	DT
cord-348535-tvs1snq8	54	44	need	need	NN
cord-348535-tvs1snq8	54	45	for	for	IN
cord-348535-tvs1snq8	54	46	an	an	DT
cord-348535-tvs1snq8	54	47	evidence	evidence	NN
cord-348535-tvs1snq8	54	48	base	base	NN
cord-348535-tvs1snq8	54	49	Favipiravir	Favipiravir	NNP
cord-348535-tvs1snq8	54	50	versus	versus	IN
cord-348535-tvs1snq8	54	51	Arbidol	Arbidol	NNP
cord-348535-tvs1snq8	54	52	for	for	IN
cord-348535-tvs1snq8	54	53	COVID-19	COVID-19	NNP
cord-348535-tvs1snq8	54	54	:	:	:
cord-348535-tvs1snq8	54	55	A	a	DT
cord-348535-tvs1snq8	54	56	Randomized	Randomized	NNP
cord-348535-tvs1snq8	54	57	Clinical	Clinical	NNP
cord-348535-tvs1snq8	54	58	Trial	Trial	NNP
cord-348535-tvs1snq8	54	59	.	.	.
cord-348535-tvs1snq8	55	1	medRxiv	medRxiv	NNP
cord-348535-tvs1snq8	55	2	S.O.	S.O.	NNP
cord-348535-tvs1snq8	55	3	and	and	CC
cord-348535-tvs1snq8	55	4	J.S.	J.S.	NNP
cord-348535-tvs1snq8	55	5	wrote	write	VBD
cord-348535-tvs1snq8	55	6	the	the	DT
cord-348535-tvs1snq8	55	7	manuscript	manuscript	NN
cord-348535-tvs1snq8	55	8	and	and	CC
cord-348535-tvs1snq8	55	9	approved	approve	VBD
cord-348535-tvs1snq8	55	10	the	the	DT
cord-348535-tvs1snq8	55	11	final	final	JJ
cord-348535-tvs1snq8	55	12	version	version	NN
cord-348535-tvs1snq8	55	13	.	.	.
cord-348535-tvs1snq8	56	1	None	none	NN
cord-348535-tvs1snq8	56	2	.	.	.
cord-348535-tvs1snq8	57	1	J.S.	J.S.	NNP
cord-348535-tvs1snq8	57	2	conflicts	conflict	NNS
cord-348535-tvs1snq8	57	3	can	can	MD
cord-348535-tvs1snq8	57	4	be	be	VB
cord-348535-tvs1snq8	57	5	found	find	VBN
cord-348535-tvs1snq8	57	6	at	at	IN
cord-348535-tvs1snq8	57	7	https://www.nature.com/onc/editors	https://www.nature.com/onc/editor	NNS
cord-348535-tvs1snq8	57	8	but	but	CC
cord-348535-tvs1snq8	57	9	none	none	NN
cord-348535-tvs1snq8	57	10	are	be	VBP
cord-348535-tvs1snq8	57	11	relevant	relevant	JJ
cord-348535-tvs1snq8	57	12	to	to	IN
cord-348535-tvs1snq8	57	13	this	this	DT
cord-348535-tvs1snq8	57	14	piece	piece	NN
cord-348535-tvs1snq8	57	15	.	.	.
cord-348535-tvs1snq8	58	1	S.O.	S.O.	NNP
cord-348535-tvs1snq8	58	2	reports	report	VBZ
cord-348535-tvs1snq8	58	3	no	no	DT
cord-348535-tvs1snq8	58	4	conflicts	conflict	NNS
cord-348535-tvs1snq8	58	5	.	.	.